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Summary 
 
Chemokines are well known to play a major role in tumor progression and 
metastasis. In particular CCL2 is over-expressed in several human cancers and their higher 
levels correlate with poor prognosis and shorter outcomes. Here we reported two different 
studies in which CCL2 receptors, the canonical CCR2 and the atypical D6 (or ACKR2) were 
examined for their involvement in tumor progression. In particular D6 was investigated for 
its expression and its ability to shape CCL2 gradient in Kaposi’s sarcoma, whereas CCR2 has 
been analyzed as potential modeler of TAM polarization. 
D6 is an atypical chemokine receptor acting as a decoy and scavenger for 
inflammatory CC chemokines expressed in lymphatic endothelial cells. Here, we report that 
D6 is also expressed by Kaposi’s sarcoma (KS) which is a tumor ontogenetically related to 
lymphatic endothelium, yet its role in tumor progression was hitherto unknown. D6 
expression was evaluated by immunohistochemistry in a cohort of KS patients and its role in 
cancer progression was investigated in an in vivo KS model. Both in human tumors and in the 
experimental model, D6 expression levels were inversely correlated with tumor 
aggressiveness, and directly correlated with increased chemokine-driven infiltration of 
macrophages and their acquisition of a pro-angiogenic phenotype. Inhibition of monocyte 
recruitment reduced growth of D6-incompetent tumors, while adoptive transfer of wt but 
not CCR2
-/-
 macrophages increased the growth rate of D6-competent neoplasms. In the KS 
model, which presents the B-Raf V600E activating mutation, inhibition of B-Raf or 
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downstream ERK pathway induced D6 expression, and in progressing human KS tumors 
activation of the K-Ras/B-Raf/ERK pathway correlate with reduced levels of D6 expression. 
These results indicate that activation of the K-Ras/B-Raf/ERK pathway during KS progression 
down-regulates D6 expression, which unleashes chemokine-mediated macrophage 
recruitment and their acquisition of an M2-like phenotype supporting angiogenesis and 
tumor growth. 
Thereafter, we wanted to deeper investigate how CCR2 support TAM M2 polarization 
firstly by using an in vitro system. Wt and CCR2
-/-
 macrophages were polarized with M1 and 
M2 stimuli and analyzed for gene expression and cytokines production. While no difference 
was found in M2 polarized macrophages, CCR2
-/-
 M1 or LPS activated macrophages showed 
higher expression of inflammatory genes and reduced production of the anti-inflammatory 
cytokine IL-10 and of the pro-angiogenic cytokine VEGF when compared to wt macrophages. 
The impaired IL-10 production was also confirmed by treating human monocytes with the 
CCR2 antagonist RS-504393. After LPS stimulation, CCR2
-/-
 macrophages showed reduced 
activation of NF-kB and p38 MAPK when compared to wt macrophages indicating a cross talk 
between CCR2 and TLR4 signaling pathways. The contribution of CCR2 to cancer growth was 
evaluated with a transplantable lung cancer model that grew slower when co-injected with 
CCR2
-/- 
macrophages, presenting a marked M1 phenotype of infiltrating TAM and a higher 
number of both CD4+ and CD8+ T cells, correlated with a decreased number of splenic T 
regulatory cells when compared to wt macrophages holding-tumors. Taken together these 
data indicate that CCR2 expression by macrophages not only induce their recruitment to 
tumor site but also affect their polarization and anti-tumor potential. 
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1. Introduction 
 
1.1. The mononuclear phagocyte system 
The monocyte-macrophage system has been first described by Metchnikoff in the 
late 19
th
 century, depicting them as phagocytes, mesodermal cells able to internalize and 
digest bacteria and other cells [1]. In the 1970s Van Furth and Cohn established the 
mononuclear phagocyte system (MPS), a linear model proposing that committed bone 
marrow (BM) precursors differentiate into blood monocytes from which tissue macrophages 
derive, in the steady state and during inflammation [2]. In agreement with this model, 
circulating monocytes has been described to extravasate from the blood and give rise to 
inflammatory macrophages in response to inflammatory signals or other stimuli, like tumor 
progression and wound healing [3], [4], [5]. However, this model has always been disputed 
because of a large number of observations contrasting macrophages belonging to MPS. In 
fact from the literature it is known that during embryogenesis macrophages are already 
present in the yolk sac before primitive hematopoiesis [6, 7]. Moreover tissue-resident 
macrophages are not affected in monocytopenic mice [6, 8], do not exchange in parabiotic 
mice [9], [10] and are only partially replaced after irradiation and bone marrow replacement 
[11]. Concluding, now it has been established the existence of two models of myeloid cell 
differentiation that coexist during embryogenesis and adulthood. 
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1.1.1. Monocyte and macrophage ontogenesis 
Adoptive transfer experiments and analysis of syngeneic BM transplantation have 
clearly shown that circulating monocytes, some macrophage subsets and the classical 
dendritic cell (DC) lineage [12] originate in vivo from hematopoietic stem cells (HSC). In 
murine hematopoiesis, the multipotent capability resides in a small fraction of BM cells 
called LSK, characterized as Lin- Sca-1+ c-kit+ (Figure 1.1). Within the LSK fraction it is 
possible to distinguish, by CD34 staining, the most primitive self-renewing HSC which have a 
long term reconstituting activity and are CD34-. The other components of LSK are CD34+ 
multipotent progenitors (MPP) only capable of a transient reconstitution [13]. Successive 
committed step in the BM include common lymphoid progenitor (CLP) and common myeloid 
progenitor (CMP) (Figure 1.1). The last one is characterized as IL-7Rα- c-Kit+ Lin- Sca-1- and 
can be further fractionated on the basis of the expression of FcγRII and FcγRIII (CD16/CD32) 
and CD34. CMP (FcγRII/III
lo
 CD34+) differentiate into granulocyte-macrophage precursors 
(GMPs: FcγRII/III
hi
 CD34+) and megakaryocyte-erythrocyte precursors (MEP: FcγRII/III
lo
 
CD34-)[14], [15]. Subsequently CMP differentiate into a monocyte/macrophage and DC 
precursor (MDP), a subset of proliferating cells in the BM that give rise to monocytes and to 
the common DC precursor (CDP). Of note, the development of monocytes is dependent on 
the growth factor receptor Csf-1R (MCSF-R or CD115) [16], [17], indeed Csf1r deficiency 
causes a reduced number of circulating monocytes [18]. Recently, gene invalidation in mice 
allowed the identification of genes required for generation and maintenance of progenitor 
and hematopoietic stem cells. One of this genes is the transcription factor Myb, required for 
the development of HSPC and monocytes, macrophages and DC [19], [20]. 
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Figure 1.1 - The hematopoietic tree. Hematopoietic stem cells (HSCs) have the capacity to self-renew 
and to give rise to all the cell types of the bone marrow and peripheral blood. Other pluripotent 
progenitors, short-term HSCs and multipotent progenitors (MPPs) have less self-renewal capacity. 
Together, these three cell types constitute the hematopoietic stem and progenitor cell (HSPC) 
population. MPPs are thought to differentiate into the two main branches of hematopoietic 
development that arise from the common lymphoid progenitor (CLP) and the common myeloid 
progenitor (CMP). Mature peripheral blood cells, shown on the right, are derived from these 
progenitors. GMP, granulocyte and macrophage progenitor; MEP, megakaryocyte and erythrocyte 
progenitor; NK, natural killer [21]. 
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In contrast to myeloid cells produced continually by the BM, tissue-resident 
macrophages develop in the embryo before the appearance of HSC and persist in adulthood 
[22]. In mice, macrophages start to develop at embryonic day 8 from the primitive ectoderm 
of the yolk sac and generate macrophages that do not have a monocytic progenitor and can 
be distinguished in several tissues as “F4/80 bright”, for example liver Kupffer cells, 
epidermal Langerhans cells and microglia (Figure 1.2) [20]. Schulz et al [20]recently 
demonstrated, by fate-mapping studies, that this macrophages arise from precursor cells in 
the yolk sac independently from the transcription factor Myb whereas they are mainly 
regulated by CSF1R and its ligands, IL-34 and CSF1 [23]. Proliferative local expansion of tissue 
macrophages in neonatal period, followed by low-level of self-renewal during adulthood 
maintain tissue resident populations. Indeed two independent groups confirmed that tissue 
macrophages are able to self-renew independently from monocytes or BM progenitors [24], 
[25]. Nevertheless, experimental ablation of resident macrophages demonstrated the ability 
of BM-derived cells to replace self-renewing resident cells but it is not clear if these 
converted cells fully recapitulate the function of those replaced [26].  
 
 
 
Figure 1.2 - A redefined model of macrophage lineages in mice. The mononuclear phagocytic system 
derives from at least two sources. The first is the yolk sac, which produces progenitors that populate 
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all tissues and that have progeny that persist throughout life as F4/80 bright resident macrophages. 
These lineages are mainly regulated by CSF1R and its ligands, IL-34 and CSF1. Moreover progenitors 
from the yolk sac can seed in the fetal liver and contribute to the production of adult Langerhans 
cells. The second lineage derives from the bone marrow (BM) to give circulating monocytes and their 
progeny F4/80
low
 macrophages, and dendritic cells (DCs). Other macrophages that are F4/80
low
 also 
emanate from Ly6C
+ 
monocytes, and in some cases, such as in kidney and lung, they co-exist with 
those derived from the yolk sac to give chimeric organs. The exact role of the patrolling Ly6C
–
 
macrophages, and the contribution of fetal liver to adult tissue macrophages, remain unclear. CDP, 
committed dendritic cell progenitor; MDP, monocyte dendritic cell progenitor [27].  
 
1.1.2. Monocytes  
Monocytes are a heterogeneous cell population consisting in several functional 
subsets that can be divided on the basis of chemokine receptor expression and the presence 
of specific surface molecules. In mice, they are classified in classical “inflammatory” and non-
classical “resident” monocytes [5], [28], [4] (Figure 1.3). Classical monocytes, representing 
approximately 2-5% of circulating leukocytes, express high levels of Ly6C (Ly6C
high
), the 
chemokine receptor CCR2, the adhesion molecule L-selectin (CD62L) and low levels of 
CX3CR1. They owes the name to their pro-inflammatory phenotype since they secrete 
inflammatory cytokines, like TNF-α and IL-1 during infections or tissue damage and are 
selectively recruited to inflamed tissues and lymph nodes in vivo [28], [4]. Moreover upon 
inflammatory stimuli they translocate from the bone marrow into circulation. BM egress is 
CCR2-dependent but may also involve other pathways such as CXCR4/CXCL12 and when 
inflammatory signals hold off, Ly6C
high
 monocytes shuttle back to the bone marrow and 
down regulate CCR2 [3, 29]. During inflammatory events, Ly6C
high
 monocytes can 
differentiate into a variety of macrophages and DCs. Indeed during infection with Listeria 
monocytogenes, Ly6C
high
 monocytes have been reported to differentiate into DCs that 
produce inflammatory mediators such as TNF-α, nitric oxide and reactive oxygen species, 
known as TipDC [29], [30], whereas in several tumors, up to a half of myeloid derived 
suppressor cells (MDSC), cells that promote tumor growth by suppressing T cell response, 
are Ly6C
high
 [31].  
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The second subset of murine monocytes is characterized by high expression of 
CX3CR1 and lack of expression of Ly6C (Ly6C
low
), CCR2 and L-selectin [5, 28]. Firstly, they 
were called “resident” because of their long half-life in vivo and their localization in both 
resting and inflamed tissues after adoptive transfer [5]. Intravital microscopy revealed that 
they patrol blood vessels by crawling across the endothelium, suggesting that they are 
ideally located to survey endothelial cells and surrounding tissues for damage or infections 
[32]. Moreover, transcriptional profiling of extravaseted monocytes after Listeria 
monocytogenes infection show that Ly6C
low 
monocytes initiate a macrophage differentiation 
program resembling the one describing for “alternative activated macrophages”[33]. Finally 
adoptive transfer experiments demonstrate that Ly6C
high
 monocytes can shuttle between 
the blood and the bone marrow and lose Ly6C expression, suggesting that they give rise to 
Ly6C
low 
monocytes [34, 35]. However, gene ablation and antibody-mediated depletion of 
Ly6C
high
 monocytes did not affected the generation of Ly6C
low 
monocytes [11, 36-38]. 
In humans, three subset of circulating monocytes are defined: classical monocytes 
(CD14++CD16-), intermediate (CD14+CD16+) and non-classical monocytes (CD14
low
CD16+) 
(Figure 1.3) [39, 40]. Classical monocytes represent 80-90% of circulating monocytes and, 
expressing high levels of CCR2, have a phenotype resembling Ly6C
high
 murine monocytes but, 
after LPS stimulation, they release the immune suppressing cytokine IL-10 [41, 42]. In turn, 
intermediate and non-classical monocytes express high levels of CX3CR1 a low levels of CCR2. 
CD14+CD16+ also express Fc receptors CD64 and CD32 have high phagocytic activity and 
produce TNF-α and IL-1 in response to LPS, whereas non-conventional monocytes are poorly 
phagocytic but are more potent antigen presenting cells [43, 44].  
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Figure 1.3 – Murine and human monocyte classification. Hematopoietic stem cells produce a 
monocyte, macrophage and dendritic cell precursor (MDP) in the bone marrow via a myeloid 
committed precursor (CMP). MDPs give rise to monocytes, possibly through a Gr1+ pro-monocyte 
(dashed line), and pre-classical dendritic cells (Pre-cDC) and plasmacytoid dendritic cells (PDC) via a 
common dendritic cell precursor (CDP). In the mouse, two monocyte subsets Ly6C
high
 and Ly6C
low
 
leave the bone marrow to enter the circulation. The corresponding human monocyte subsets are 
shown in the light and dark purple boxes: inflammatory murine Ly6C
high
 and two human CD14+ 
subsets; and murine Ly6C
low
 and human CD14
low
 monocyte subsets. CD14+ monocytes respond to 
cells surface TLRs and are involved in inflammation and leukocyte recruitment, while CD14
low
 
monocytes sense tissue damage and respond to viruses and nucleic acids via endosomal TLRs 
(TLR7,8) [45]. 
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1.1.3. Macrophages  
Mature macrophages are strategically located throughout the body and, reflecting the 
specialization of function that they adopted in different anatomical locations, they perform 
different roles in clearance, development, regulation of metabolism and an important 
immune surveillance function. For example, alveolar macrophages facilitate the removal of 
allergens from the lung [46-48], Kupffer cells participate in the clearance of pathogens and 
toxins from circulation and adipose tissue macrophage regulate insulin sensitivity and 
adaptive thermogenesis (Figure 1.4) [2]. Moreover, the gut is one of the richest sources of 
macrophages in the body, and isolation of macrophages from the lamina propria has 
highlighted a unique macrophage phenotype, characterized by high phagocytic and 
bactericidal activity but weak production of pro-inflammatory cytokines. This phenotype can 
be induced in peripheral-blood-derived macrophages by intestinal stromal-cell products, 
indicating that the tissue microenvironment can markedly influence the phenotype of tissue-
resident macrophages [49]. 
 
1.1.3.1. Macrophage functions 
Owing to their strategic location, closed to sites of injury, tissue resident 
macrophages play a central role in the innate recognition of a range of pathogens, by 
mounting proper and effective immune response. In fact, after pathogen recognition, tissue 
macrophages through inflammatory chemokines production, drive the influx of leukocytes, 
mainly neutrophils but also monocytes as precursors of inflammatory macrophages [50]. 
These monocyte-derived macrophages rapidly dominate many inflammatory lesions, being 
in greater number than resident macrophages. They show an inflammatory phenotype and 
secrete pro-inflammatory mediators as TNFα, NO and IL-1 but the excessive inflammation 
must be balance in order to protect tissue integrity [51]. Indeed, uptake of apoptotic 
neutrophils can stimulate macrophages to produce anti-inflammatory molecules, like IL-10, 
TGFβ, PGE2 and VEGF which not only prevent the killing of tissue-resident cells but also 
contribute to repair after tissue injury. Moreover, it has been demonstrated that during 
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helminthic infection, IL-4 supports tissue-resident macrophages proliferation and 
consequently causes their accumulation resulting in the worm expulsion [52]. 
 
 
Figure 1.4 – Different functions of tissue-resident macrophages. Tissue-resident macrophages have 
broad roles in clearance (degradation of erythroid nuclei, senescent erythrocytes, apoptotic cells and 
pulmonary surfactant), development (bone degradation and angiogenesis) and the regulation of 
metabolism (regulation of insulin sensitivity and adaptive thermogenesis in adipose tissue). They also 
have a fundamental role as an immune sentinel, initiating inflammatory responses, clearing 
inflammatory debris and restoring homeostatic tissue environments [2]. 
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1.1.3.2. Macrophage polarization 
Macrophages have been functionally grouped in two classes: M1 or “classically 
activated” and M2 or “alternatively activated” (Figure 1.5). Classically activated 
macrophages develop in response to NK and Th1 product IFN-γ, in concomitant exposure to 
microbes or microbial products such as LPS [53]. The hallmark of classically activated 
macrophages is the increased secretion of pro-inflammatory cytokines and enhanced ability 
to kill intracellular pathogens [54]. Their inflammatory repertoire is characterized by the 
secretion of pro-inflammatory mediators, like TNFα, IL-6, IL-12, IL-1β, inflammatory 
chemokines as CCL2, CCL5 and CXCL8, and the release of reactive oxygen and nitrogen 
intermediates (ROI and RNI) [55, 56]. Other genes associated to M1 phenotype encode the 
enzyme indoleamine-pyrrole 2,3 dioxygenase and NO synthase 2 (iNOS2) [57] which are 
involved in microbicidal activity and co-stimulatory molecules such as CD80 and CD86 [58]. 
On the contrary alternatively activated macrophages have anti-inflammatory function and 
regulate wound healing. They have recently been divided into three groups: M2a, induced 
by IL-4 and IL-13; M2b induced by immune complexes and agonists of TLRs or IL-1 receptors; 
and M2c, induced by IL-10 and glucocorticoid hormones [59]. M2 macrophages produce 
anti-inflammatory cytokines like IL-10, IL-19 and IL-20 and are characterized by the up-
regulation of Yim1/2 and mannose receptor whereas down-regulate inflammatory cytokines 
[60]. Moreover they express high levels of the enzyme arginase-1 (ARG1) and down-regulate 
iNOS2, thus skewing the metabolic pathway of NO to the production of proline. 
Consequently these cells fail to produce NO and are significantly compromised in their 
microbicidal ability for intracellular pathogens, compared to M1 activated macrophages 
(although they may acquire microbicidal activity to other pathogens) [61]. Alternatively 
activated macrophages also produce growth factors that stimulate epithelial cells and 
fibroblasts, including transforming growth factor-β1 (TGFβ1) and PDGF which contribute to 
tissue regeneration and wound repair [62]. 
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Figure 1.5 – Schematic representation of macrophages polarization. M1 or classically activated 
macrophages are highly inflammatory and release pro-inflammatory cytokines/chemokines as TNF-α, 
IL-1β, IL-6, MCP-1 and superoxide anion. These macrophages also express iNOS and are activated by 
IFN γ and LPS. Conversely, M2 or alternative activated macrophages release high levels of IL-10 in 
parallel with reduced levels of TNFα, IL-6, and MCP-1. M2 macrophages are alternatively activated 
macrophages, originally identified after IL-4 and IL-13 stimulation, that up-regulate scavenger, 
mannose (CD206), RELM-α, and show chitinases Ym1 and Ym2 expression and arginase 1 activity 
[63]. 
 
1.1.3.3. Tumor associated macrophages 
Tumor microenvironment is inflammatory and that activation of the immune system 
plays a role in progression of cancer [64-66]. Indeed, plasticity of macrophage function is 
well described, and evidences suggest that tumor-associated macrophages (TAM) are 
involved in complex crosstalk with tumor cells and other cells of tumor microenvironment 
[67-69]. Moreover there is an extensive literature showing that macrophages are not only 
important for tumor progression but also in promoting tumor cell survival, angiogenesis and 
metastatization, in fact they have been demonstrated fundamental for malignant cell 
migration and invasion in different tumor models [70]. Tumor microenvironment, by the 
presence of tumor cell products, including extracellular matrix components, IL-10, CSF-1, and 
chemokines (CCL2, CCL18, CCL17, and CXCL4), is thought to “educate” TAM towards a 
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tumor-promoting M2 phenotype mediating a switch from M1 to M2 phenotype during 
tumor progression [71]. Indeed, classically activated M1-polarized macrophages exhibit 
antitumor activity and elicit tumor tissue disruption [72], whereas TAM mainly display an 
M2-like phenotype, expressing high levels of IL-10, Mannose receptor and low levels of IL-12. 
TAM infiltration is generally associated with poor prognosis, as shown in Hodgkin disease, 
glioma, cholangiocarcinoma, and breast carcinoma [73, 74]. However, TAMs with various 
functional states can coexist in the same tumor [66, 75].  
 
1.2. Chemokines  
Chemotactic cytokines, or chemo-kines, are a large subfamily of cytokines that direct 
the recruitment of circulating leukocytes to sites of inflammation. To date, approximately 50 
human chemokines and 20 receptors have been discovered. They are a single polypeptide 
chain proteins composed of 70-100 aminoacid residues in length, with a molecular weight of 
8-12 KDa and 20-95% sequence identity to each other including conserved cysteine residues 
that have also been used for subfamily definition and nomenclature. A characteristic of the 
chemokine system is the binding promiscuity of chemokines and chemokine receptors: most 
chemokine receptors interact with more than one chemokine ligand and most ligands 
recognize multiple receptors. This applies in particular for the inflammatory chemokines, 
whereas homeostatic chemokines display a more selective relationship with their receptors 
[76, 77]. Moreover, chemokines display also high degree redundancy in leukocyte migration, 
despite the cell-specific expression of defined chemokine receptors. This property is the 
result of recurrent gene duplications during evolution [78] [79]. Most chemokine genes are 
clustered in defined chromosomal locations. These clusters originate from repeated 
duplications of genomic regions and contain genes encoding many ligands which interact 
with only a selective set of receptors and may have similar effector functions. 
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1.2.1. Chemokine classification 
Chemokines can be classified into subgroups on the basis of their structure or 
function [78, 80-82]. Looking at the function, they can be divided in inflammatory and 
homeostatic chemokines. Inflammatory chemokines are inducible and secreted during 
inflammatory responses after infection or tissue injury and they are responsible for 
recruitment of effector leukocytes to the site of inflammation. In contrast, homeostatic 
chemokines are constitutively produced by tissue cells and control basal leukocyte 
trafficking, such as lymphocyte homing to secondary lymphoid organs and lymphocyte 
recirculation through peripheral tissues. Some chemokines exert both inflammatory and 
homeostatic functions, depending on the biological context or pathological state, and are 
therefore called dual-function chemokines. On the other hand, chemokines and their 
receptors have been traditionally structurally classified into four subfamilies based on the 
location of the two NH2-terminal cysteine residues: CC, CXC, C, and CX3C (Figure 1.6). In 
2000, a system of nomenclature has been introduced identifying each ligand and receptor by 
its subfamily and given an identifying number [83, 84]. The bigger family consists of CC 
chemokines, which have the first two of the four cysteine residues in adjacent positions. CC 
chemokines mainly attract mononuclear cells, such as monocytes, T and B lymphocytes, to 
sites of inflammation. The most deeply characterized CC chemokine is CCL2, also called 
monocyte chemoattractant protein 1 (MCP-1) that is a potent agonist for monocytes, 
dendritic cells, memory T cells, and basophils. Other CC chemokines include CCL3 
(macrophage inflammatory protein (MIP)-1α), CCL4 (MIP-1β) and CCL5 (RANTES) [85]. The 
second bigger family of chemokines consists of CXC chemokines, which have a single amino 
acid residue interposed between the first two canonical cysteines. Most CXC chemokines 
attract polymorphonuclear leukocytes to sites of inflammation. The third family is the CX3C 
family composed of only one member: fractalkine (CX3CL1) [86] [87]. It is expressed as 
transmembrane molecules, having the chemokine domain fused to a mucin-like stalk. It can 
be cleft by tumor necrosis factor (TNF)-α–converting enzyme and so being able to function 
as a soluble chemoattractant. The last family is also composed of one member, called 
lymphotactin (XCL1), which has a single cysteine residue [88]. 
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Figure 1.6: – Chemokine structure and classification. Chemokines are subdivided into 4 families on 
the basis of location of the two NH2-terminal cysteine residues: CC, CXC, C, and CX3C [89]. 
 
1.2.2. Chemokine structure 
In general, chemokines contain four well conserved cysteine residues, which form 
two cysteine bridges that are responsible for their specific tertiary structure. Indeed, despite 
the low overall amino acid sequence homology among chemokines, they all share 
remarkably conserved tertiary structure. This consist of a disordered N-terminus of 6–10 
amino acids, which functions as a key signaling domain in all chemokines characterized to 
amino acids, which functions as a key signaling domain in all chemokines characterized to 
date. This region is followed by the N-loop, a long loop containing important binding 
determinants that ends in a α-helix, a three-stranded β-sheet, and a C-terminal helix. 
Disulfide bonds stabilize the overall topology. Moreover, many chemokines form dimers and 
higher order oligomers alone in solution or upon binding to glycosaminoglycans (GAGs) [90] 
[91], whereas only few chemokines are known to form tetrameric structures. 
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1.2.3. Chemokine functions 
The principal and more studied function of chemokines is to direct cell migration. 
This process involve may sequential interactions involving adhesion molecules, GAGs, but 
obviously also chemoactractant ligands and their receptors [92] [93]. First, selectins 
expressed on the endothelium interact with mucin receptors on leukocytes through labile 
interactions, causing a rolling behavior of the leukocyte along the cell surface [94]. 
Chemokines, secreted in response to proinflammatory cytokines, bind GAGs on the 
endothelial cell surface creating a cell surface gradient [85]. The role of inflammatory 
chemokines is to induce the migration of leukocytes to the injured or infected site, but, their 
roles are more complicated and depend on the physiological context. In the last few years 
chemokines have been recognized as important mediators in the pathogenesis of many 
human diseases and have assumed growing relevance in clinical pathology as markers of 
disease onset, progression, and remission. Indeed, chemokines play also non chemotactic 
functions. For example, they modulate angiogenesis and fibrosis [95], regulate 
differentiation processes and proliferation of hematopoietic progenitors [80], are involved in 
ontogenesis of vascular and nervous system [96], control cell survival and co-stimulate T cell 
[97]. 
 
1.3. Chemokine receptors 
Chemokines exert their biological functions through the interaction with their 
membrane receptors, which belong to seven transmembrane domain G protein coupled 
receptors (GPCR) and in particular to the rhodopsin-like family [98] [99]. The structure of 
chemokine receptors (CKR) consists of a single polypeptide chain crossing seven times the 
cell membrane, consequently generating three extracellular and three intracellular loops. 
The acidic amino-terminal extracellular domain is fundamental for ligand binding and 
contributes to the specificity of ligand recognition. The conserved transmembrane 
sequences, the cytoplasmic loops and the C-terminal domain, rich in phosphorilable 
serine/threonine are involved in receptor internalization and signal transduction. Chemokine 
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receptor’s structure hold structural motifs, important for signaling: an aspartic acidic 
residue, a Thr-X-Pro (TXP; where X denotes any amino acid) motif in the second 
transmembrane domain and the DRYLAIV motif in the second intracellular loop which 
determine the receptor coupling with G-proteins [100].  
The interaction between chemokines and their receptor is a two-step process, 
involving two important sites present in chemokine structure and kept in close proximity by 
a disulphide bonds: docking and triggering domain. The first one is represented by the 
conformationally rigid loop that follows the second cysteine and is firstly recognized by the 
N-terminus of the receptor. This interaction restricts the mobility of the chemokine and 
presumably facilitates the proper orientation of the triggering domain that corresponds to 
the chemokine N-terminal domain and is thought to lead the receptor activation [98, 101-
103]. 
Chemokine receptors have been demonstrated to be coupled to hetero-trimeric GTP-
binding proteins (G-protein) of the Gi type, sensitive to Bordetella pertussis toxin. Upon 
receptor engagement, G-proteins are activated by exchanging GDP with GTP and inducing 
the dissociation of α subunit from Gβγ complex. Whereas α subunit inhibits adenylate 
cyclase, the βγ subunit induces the reorganization of the actin cytoskeleton, cell migration, 
increase in intracellular calcium and activation of specific gene transcription [104]. All these 
processes are supported by the βγ subunit activation of phospholipase Cβ2 (PLC-β2) which 
causes the formation of inositol-1,4,5- trisphosphate (InsP3) and diacylglycerol (DAG) and a 
transient increase of intracellular free calcium concentration. DAG production leads to 
protein kinase C (PKC) activation which contributes to receptor phosphorylation and 
consequently desensitization and inhibition of functional responses, through the β-arrestin 
recruitment. Other pathways activated after chemokine binding comprehend 
phosphatidylinositol 3 kinase γ (PI3K γ) which activate MAPKs [105] (Figure 1.7). 
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Figure 1.7: – Chemokine receptor signaling pathway. Scheme of the most effectors of the signal 
transduction present in chemokine signal transduction [104]. 
 
1.3.1. CCR2 
CCR2 is a chemokine receptor that belongs to the subclass of CC receptors and binds 
inflammatory chemokines such as CCL2 (MCP-1), CCL8 (MCP-2), CCL7 (MCP-3), CCL13 (MCP-
4), CCL11 (Eotaxin-1), CCL24 (Eotaxin-2), CCL26 (Eotaxin-3), with different affinity. It is 
expressed by hematopoietic cells, in particular by monocytes, but also by non-hematopoietic 
cells, such as endothelial cells [106], fibroblasts [107], mesenchymal stem cells [108] and 
several tumor cell lines including prostate, lung, breast cancer, and myeloma cell lines. The 
most studied CCR2 ligand is CCL2 also known as monocyte chemoattractant protein-1 (MCP-
1). This chemokine is a potent in vitro monocyte activator and is one of the main responsible 
for monocyte traffic. CCL2 is a 76 amino acid polypeptide whose gene is localized in a cluster 
of genes encoding for cytokines on the q-arm of chromosome 17 [109]. It was purified in 
1989 and since then it has been found to chemoactract not only monocytes, but also 
memory T cells, natural killer (NK) cells, and perhaps dendritic cells.  
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1.3.1.1. CCR2 and monocyte traffic 
CCR2 and its two ligands CCL2 and CCL7 play a crucial role in monocyte egression 
from bone marrow and their recruitment at site of inflammation. The important role of CCR2 
in mobilization of hematopoietic cells from BM was firstly individuated by Charo et al in 2007 
[110]. In this study they found CCR2
-/-
 mice to show in homeostatic conditions a marked 
decrease in circulating Ly6C
high
 inflammatory monocytes, whereas they showed a normal or 
increased number of monocytes in the bone marrow. These data suggested that CCR2
-/-
 mice 
present a defect in monocyte mobilization rather than monocyte differentiation and CCL2 
and CCL7 have been demonstrated to be the CCR2 ligands responsible for that defect. In fact 
only mice deficient for these two chemokines showed the same defect present in CCR2
-/-
 
animals, whereas MCP-5
-/-
, MCP2
-/-
 mice exhibit a normal blood monocyte number.  
By other studies CCR2 resulted to be crucial not only for homeostatic monocyte 
mobilization, but also in response to inflammatory stimuli. In fact, Serbina et al examined 
the importance of CCR2 in different stages of monocyte migration in a setting of L. 
monocytogenes infection [3] and found that Ly6C
high
 monocyte egression into circulation is 
enhanced by inflammation or infections. Moreover, further studies demonstrated that 
during infections low concentrations of TLR ligands in the bloodstream induce CCR2-
dependent emigration of monocytes from bone marrow. This is caused by rapid production 
of CCL2 by bone marrow mesenchymal stem cells and CXCL12 abundant reticular (CAR) cells 
in response to TLR ligands or bacterial infections [111] (Figure 1.8).  
However CCR2 importance in monocyte egression from BM is confirmed, its role in 
monocyte recruitment at inflammation site in still controversial. Indeed, in setting of L. 
monocytogenes infection monocyte recruitment in spleen was demonstrated to be CCR2-
independent. However, others studies reported that in West Nile Virus (WNV) and protozoal 
infections the axis CCL2-CCR2 is crucial not only for the monocyte traffic from the bone 
marrow to the circulation but also for their recruitment to the inflammation sites [112]. 
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Figure 1.8: – CCR2-dependent LY6C
high
 monocytes egression from the bone marrow. CCL2 is 
produced in homeostatic conditions and increased during infection, by BM MSC or CAR cells and 
induce monocyte egression from BM into the bloodstream [113]. 
 
1.3.1.2. CCR2 and cancer 
CCL2/CCR2 axis has a crucial role in several chronic inflammatory conditions such as 
atherosclerosis [114, 115], multiple sclerosis [116], rheumatoid arthritis [117] and cancer. 
Indeed, CCL2 is expressed in different tumors, like prostate, breast, lung, melanoma, ovary, 
gastric, renal, colorectal, esophageal and multiple myeloma. In prostate cancer CCR2 
expression levels has been correlated with tumor aggressiveness and higher expression have 
been found in the more aggressive cell lines [118]. Moreover CCL2 expression in tumor cells 
significantly correlates with tumor-associated-macrophage (TAM) infiltration, and in breast 
cancer CCL2 expression has been positively correlated with VEGF production, TAM 
infiltration, angiogenesis, and poor survival [119]. Tumor supporting effects of CCL2 are 
different and comprehend the induction of cancer cell proliferation through the activation of 
(PI3K)/AKT pathway, promotion of cancer cell extravasation and metastatization and 
induction of angiogenesis (Figure 1.9) [118, 120]. In colonic adenoma CCL2 has been 
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demonstrated to stimulate the production of the pro-angiogenic cytokine VEGF through 
pathway of COX-2/PGE2 in both autocrine and paracrine manner [121]. All these evidences 
suggested that CCL2/CCR2 axis could be a target for cancer treatment. In vivo experiments 
indicate that administration of neutralizing antibody against CCL2 significantly reduce tumor 
blood vessel density and decrease tumor burden [120, 122]. Moreover, CCR2 antagonist in 
prostate cancer patients has been shown to decrease cancer cell proliferation and invasion 
in vitro [123]. Growing evidences in several cancer types, like prostate, breast cancer and 
myeloma, suggest that CCL2 can directly promote cancer epithelial cell migration and 
invasion, enhancing metastatic potential [124, 125]. 
 
Figure 1.9: – Tumorigenic activity of CCL2. CCL2 is tumorigenic through its direct effects on tumor 
cells and its influence on normal host cells (OC: osteoclasts) [89, 126]. 
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1.4. Atypical chemokine receptors 
Chemokines activity is thinly regulated at transcriptional, translational and post-
translational levels. One of the mechanisms regulating chemokine bioavaibility is 
represented by a sub-class of chemokine receptors, previously called decoys, interceptors, 
scavengers, or chemokine-binding proteins. Recently it has been formalized the new name 
of atypical chemokine receptors in the new Nomenclature Committee of the International 
Union of Pharmacology and Human Genome Organization Gene Nomenclature Committee 
[127]. This family of receptors is characterized by their promiscuous chemokine binding, with 
the exception of CXCR7, and their inability to couple G proteins and induce conventional G 
protein-coupled signaling. This inability is the consequence of the presence of a modified or 
missing canonical DRYLAIV motif in the second intracellular loop of the chemokine receptor, 
which is indispensable for G proteins coupling. However, recent evidences suggest that 
these receptors do signal through G protein-independent signaling pathways [128-130]. 
The family of atypical chemokine receptors is very heterogeneous in structure and 
function. Some of them have clearly been shown to scavenge chemokines and therefore to 
manipulate chemokine responses in vivo, whereas others appear to be important for the 
local regulation of chemokine presentation and function. The members of the atypical 
chemokine receptor family are: ACKR1, previously known as Duffy Antigen Receptor for 
Chemokines (DARC); ACKR2, formerly D6 or CCBP2; ACKR3, alias CXCR7; ACKR4, formerly 
CCRL1 or CCX CKR. Two more receptors could be part of this family, but pending 
confirmation: CCRL2 or ACKR5, and PITPNM3, also known as the CCL18/PARC receptor that 
would be ACKR6 [127] (Figure 1.10). 
ACKR1 or DARC is able to bind, with different affinity, more than 20 different 
inflammatory CC and CXC chemokines [131-133]. It show different functions depending on 
cell type in which it is expressed. Its expression on erythrocytes historically sticks at DARC 
the function of “sink” for chemokines, being able to regulate blood levels of inflammatory 
chemokines. On the other hand, it can be also expressed by polarized cells, in particular in 
vascular endothelial cells, like capillaries and venules in several tissues and organs. Here, 
DARC acts as transporter; in fact it binds chemokines from the baso-lateral layer and brings 
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them to the apical surface where chemokines remain associated with DARC, leading to 
chemokine presentation on the luminal microvilli [134]. 
ACKR3, alias CXCR7, has two ligands: CXCL12, which is the unique ligand of CXCR4 and 
it is bound by CXCR7 with very high affinity. The second ligand is CXCL11, whose 
conventional receptor is CXCR3, but it is bound with much lower affinity than CXCL12 [135, 
136]. ACKR3 is expressed by different cell types, including hematopoietic, mesenchymal, and 
neuronal cells [137]. In particular, its expression has been identified in different leukocyte 
population, for example in human B cells and in B cells located in murine splenic marginal 
zone [138, 139], but also in barrier organs, like placenta or brain microvessel endothelium. 
Functionally, ACKR3 has been shown to play a fundamental role in regulating CXCL12 
availability for CXCR4. Indeed, CXCR7 knock-out mice display a lethal phenotype, 
corresponding to le phenotype of CXCR4 or CXCL12 KO mice. Animals die at birth or perinatal 
because of defect in heart valves[140-142]. Moreover, this phenotype is also shown in mice 
keeping a conditional deletion of the gene in endothelial cells, suggesting a crucial role of 
ACKR3 expressed in this cell type [140]. Finally, CXCR7 has been reported to be expressed in 
different type of tumors, both of hematopoietic and mesenchymal origin [143-145], such as 
lymphomas, sarcomas, prostate and breast cancer [146, 147]. Its expression in tumors is 
often matched with CXCR4 expression, but the role of ACKR3 in cancer still remains unclear. 
ACKR4, formerly CCRL1 or CCX CKR, binds homeostatic CC chemokines, in particular 
CCL19, CCL21, CCL25 but also, with lower affinity, CXCL13 [148]. After receptor engagement, 
it is internalized and drives chemokines to the degradation in lysosomal compartment [149]. 
ACKR4 expression is still under debate, in fact it has been reported to be expressed in heart, 
lung, gut, skin keratinocytes, several lymphoid organs and thymic epithelial cells but, 
recently, CCX CKR reporter mice did not confirm the expression in heart tissues [148, 150]. 
ACKR4-/- mice, which are viable and healthy, confirmed the chemokine scavenging ability of 
this receptor, in fact higher levels of its ligands have been detected in serum and lymph 
nodes [151]. Few studies on ACKR4 in pathologies have been performed, and preliminary 
results describe it having a role in basal traffic of dendritic cells to lymph nodes and of 
embryonic thymic precursors to the thymus [151]. 
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There are two other atypical chemokine receptors, but their belonging to this family 
is still not confirmed. The first one, ACKR5, is CCRL2 and its putative murine orthologous is L-
CCR. It shares 40% of similarity with the amino acid sequence of CCR1, CCR2, CCR3 and CCR5 
and it has been recently demonstrated to bind CCL19 and the chemoactractant protein 
chemerin but without a consequently induction of cell migration and calcium fluxes [152, 
153]. CCRL2 expression has been detected in several leukocytes, such as monocytes, 
macrophages, neutrophils, DCs, T and B lymphocytes, NK cells, mast cells and also in 
hematopoietic progenitor cells [154, 155]. Conversely, its murine orthologous expression is 
restricted to DCs and macrophages [156]. The in vivo role of CCRL2 is thought to be the 
regulation of chemerin levels, increasing them locally in the inflammatory sites, in order to 
facilitate chemerin binding to its functional receptor ChemR23 [152]. The last potential 
member of the ACKR family is PITPNM3, whose new name would be ACKR6. It is member of 
the phosphatidyl-inositol transfer protein (PIPT) family, which comprehends six 
transmembrane-domain proteins, and it has been recently demonstrated to bind CCL18 and 
to be involved in breast cancer metastasis [74]. 
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Figure 1.10: – Canonical and atypical chemokine receptors. Schematic representation of canonical 
and atypical chemokine receptor specificity for ligands and leukocytes [127]. 
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1.4.1. D6 (ACKR2) 
D6, now called ACKR2, is encoded in the gene cluster of CC chemokine receptors, 
wherewith it shares 30-35% of the overall sequence identity [157]. It was cloned from 
placenta and hematopoietic stem cells in the middle of 1990s [157, 158]. It is known to bind 
promiscuously inflammatory CC chemokines, but nor homeostatic ones neither chemokines 
belonging to other classes (Figure 1.11) [159, 160]. Different evidences support the 
importance of a proline residue in position 2 (P2) in the sequence of D6 ligands [160, 161]. In 
fact, D6 ligands can be subdivided into three classes: CC inflammatory chemokines efficiently 
degraded by D6 (CCL2, CCL3L1, CCL4, CCL22, CCL14(9-74)), chemokines degraded with a less 
efficiency (CCL14 (11-74), CCL3, CCL8 (6-75)) and chemokines that are not degraded (CCL14 
(1-74) e CCL3 (5-70)). Moreover, chemokines degraded by D6 have been demonstrated to 
modify its intracellular traffic and sequence analysis revealed that all members of these 
classes of D6 ligands, with the only exception of CCL17, have a proline residue in position 2. 
These evidences suggest a relevant role for this amino acid in the induction of D6 adaptive 
redistribution on the cell membrane resulting in efficient chemokine degradation (Figure 
1.9) [160]. Furthermore, D6 ligands can be modified by CD26 protease, which remove the 
two last amino acids at the N-terminal domain of chemokines holding P2 residue [160]. 
Figure 1.11: – Amino acid sequence of D6 ligands: alignment of CC chemokines recognized by D6 
using the program clustalW2 (http://www.ebi.ac.uk). Amino acid residues conserved in all aligned 
sequences are indicated by "*”; conserved substitutions are indicated by ":"; semi-conserved 
substitutions are indicated by ".”. Grey boxed chemokines are the ones efficiently scavenged by D6.  
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1.4.1.1. D6 structure and signaling properties 
D6 structure is similar to that of conventional chemokine receptors, but it contains 
alterations in conserved domains that are essential for G protein coupling and signal 
transduction (Figure 1.12). These modifications could be the cause of D6 unconventional 
signaling. The receptor N-terminal domain contains charged aminoacid important for ligand 
recognition that is also present in conventional CKR structure. In the second transmembrane 
domain of D6 is also localized the TxP (Thr-Xaa-Pro) motif present in conventional CKR 
structure and responsible for their activation [162]. Conversely, D6 does not hold the 
aspartic acid in position 92, being mutated into an arginine. This amino acidic residue is 
thought to be required for receptor activation but its role in D6 activity has not yet been 
identified. Another important determinant in CKR structure is the DRYLAIV motif present at 
the boundary of the second intracellular loop with the third transmembrane domain. This 
motif in D6 structure is converted in DKYLEIV and it has been demonstrated to give a weak 
ligand-induced signaling activity [163]. D6 also shows a C-terminal tail longer than canonical 
CRK and containing a serine cluster with a putative 8th helix. The C-terminal domain is not 
require for receptor internalization but is fundamental to prevent receptor degradation in 
late endosomes and to allow receptor recycling after chemokine degradation [164, 165]. 
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Figure 1.12: – Structural motif in canonical CKR and ACKR2: ACKR2 (D6) hold alterations in several 
structural motif mainly important for CKR signaling, in particular in DRYLAIV motif and in the Asp 
residue [166]. 
 
In homeostatic conditions, D6 is mainly stored in intracellular peri-nuclear 
compartments and only few molecules reside on the cell membrane [167, 168]. D6 is able to 
internalize not only after chemokine engagement, as conventional CKR, but also 
constitutively in Rab5+ vesicles that bring the receptor to early endosomes, which is then 
recycled back to the plasma membrane through a rapid Rab4+ and a slow Rab11+ pathway 
(Figure 1.13) [169]. After chemokine engagement D6 is mobilized from intracellular pool and 
up-regulated on the plasma membrane through the Rab11+ vesicles with the effect of 
optimizing its degradative activity [169]. Finally, a recent work demonstrated that D6 traffic 
after chemokine engagement is β-arrestin1-dependent and that it induces a non-
conventional chemokine receptor signaling. Indeed, D6, through a β-arrestin1-dependent G-
protein independent signaling pathway, involving the cascade of Rac1- PAK1- LIMK1 cascade, 
finally induces cofilin phosphorylation and actin rearrangement [130]. 
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Figure 1.13: – Actin dynamics sustain D6 up-regulation and degradatory activity: In basal condition 
D6 is internalized in a Rab5-dependent way and it recycles to the plasma membrane through a 
Rab4/Rab11-dependent mechanism. Active cofilin maintains actin cytoskeleton organization in stress 
fibers (brown), supporting constitutive internalization and recycling of D6 to the plasma membrane. 
Stimulation with active ligands induces cofilin phosphorylation and its inactivation. In this way actin 
polymerize at plasma membrane in cortical actin (green), allowing D6 up-regulation and increasing its 
scavenging efficiency and chemokine degradation. On the other hand, D6 stimulation with neutral 
ligands (gray) does not change actin organization and cofilin activation state without affecting its 
distribution and scavenging efficiency [166].  
 
1.4.1.2. Biological functions of D6 
D6 is constitutively expressed by lymphatic endothelial cells (Figure 1.14) [170], in 
particular in the skin, gut and lung and by placenta trophoblasts [171, 172]. Moreover it has 
been reported to be expressed by several leukocytes, for example innate-like B cells (IBC) 
such as MZ B cells, B1a and B1b [173], but also some tissue macrophages [172, 174, 175], 
alveolar macrophages from chronic obstructive pulmonary disease (COPD) patients [176] 
and in a subset of vascular tumors [170]. 
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Figure 1.14: D6 expression on lymphatic endothelial cells in human skin. Human skin stained by 
anti-D6 antibody. “L”marks subcutaneous lymphatic vessels that show D6 immunoreactivity. 
 
1.4.1.2.1. Homeostatic functions 
D6 has been studied for several years, but only recently it has been shown to play an 
important role in homeostatic ones and not only in the inflammatory response. In fact, 
Savino et al reported that D6-deficient mice, in resting conditions, showed a selective 
increase of Ly6C
high
 monocytes both in the bloodstream and in the spleen, whereas they 
were decreased within the bone marrow. They also resulted to exhibit a more immature 
phenotype, expressing lower levels of CD11b, CD115 and F4/80 than wt cells. By chimera 
experiments, this defect was demonstrated to be dependent of D6 absence on the non-
hematopoietic compartment [177]. Furthermore, lack of D6 in homeostatic conditions also 
provokes an enhanced B1-cell response to CXCL13, an impairment of peritoneal B1 cell 
number and anti PC antibodies present in the serum [173], as well as increased serum 
concentration of CCL11 [172] and CCL2 [177].  
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Finally , a recent work demonstrated that D6 contributes to a selective presentation 
of CCR7 ligands by eliminating inflammatory chemokine binding to lymphatic endothelial cell 
(LEC) surface and regulating their capacity to discriminate mature and immature DCs. The 
role of D6 in correctly direct DCs migration toward lymph nodes was also reported by Lee et 
al. [178]. Moreover, McKimmi et al demonstrated that D6 expression can be regulating by 
growth factors, cytokines and tumor microenvironment, in particular by IL-6 and IFNγ, 
indicating that this receptor is over-expressed in inflammatory contexts [179]. 
 
1.4.1.2.2. Protective role of D6 during inflammatory conditions 
D6 has been shown to play a fundamental role in controlling inflammatory 
chemokine gradients and so inflammatory responses in different in vivo models (Figure 
1.15). Indeed, in two models of local inflammation D6 has been investigated. Firstly, in 
phorbol ester skin painting model, D6-null mice developed an exacerbated inflammatory 
response dependent on TNFα and then sustained by inflammatory CC chemokines, not 
efficiently cleared from inflamed tissues. Consequently, D6
-/-
 mice arose psoriasis-like 
lesions, characterized by an aberrant recruitment of T cells, mast cells and a vast 
keratinocyte proliferation and neovascularization [180]. In the second model of 
subcutaneous injection of CFA, Martinez de la Torre et al demonstrated that D6-deficient 
mice showed a worst disease characterized by premature lesions, increased necrosis and 
neovascularization. At shorter time points (e.g. day 7) inflammation evolved in macroscopic 
granuloma-like lesions in a significant percentage of D6
-/-
 animals, and only in a minority of 
wild-type littermates, whereas no differences were evident at later time points [181]. 
Interestingly, in both models increased levels of inflammatory CC chemokines were detected 
and pre-treatment with chemokine receptors blocking antibodies prevented lesion 
development, confirming that the increased inflammatory response is caused by inefficient 
control of the chemokine system in absence of D6.  
Maternal-fetal interface inflammation is also controlled by D6, which is expressed by 
invading trophoblast and syncytiotrophoblast cells, which are located between maternal 
bloodstream and fetus. The role of D6 in this context was studied by using two different in 
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vivo model of fetal loss[172]: injection in pregnant mice of LPS or anti-phospholipid 
autoantibodies purified from patients affected by antiphospholipid syndrome (APS). In both 
cases lack of D6 resulted in increased fetal loss rate due to uncontrolled levels of CC 
inflammatory chemokines and consequently increased number of infiltrating leukocytes. 
Moreover, also in humans D6 has been indirectly shown to be fundamental during 
pregnancy, in fact D6-ligand chemokines are decreased in plasma of pregnant women, even 
in the ones affected by pre-eclampsia [171].  
It seems that D6 expression in organ barriers, such as skin and placenta is directed to 
emphasize its activity of inflammation regulator, controlling chemokine distribution and 
bioavaibility into lymphatic vessels and decidua. 
Polymorphisms in D6 gene sequence were described to be correlated with grading of 
hepatic inflammation of chronic hepatitis C infected patients [182], whereas studying D6 in a 
model of liver damage induced by CCl4, an extended liver damage was obtained in mice 
lacking D6, associated to high levels of intrahepatic inflammatory chemokines and increased 
infiltration of T and NK cells [183].  
In the literature there are controversial results concerning the role of D6 in colon 
inflammation. Vetrano et al described D6
-/-
 mice to fail the resolution in DSS-induced colitis, 
because of an exacerbated inflammatory response at the expense of D6 absence on stromal 
and lymphatic compartment, as understood through chimera experiments [175]. Opposite 
results were obtained by Bordon et al, who described D6-deficient mice to have a reduction 
susceptibility to colitis and correlating it with the increased production of IL-17A by T cells. 
The two papers showed opposite results, nevertheless both reported D6 to be expressed in 
normal mucosa and up-regulated in colon samples from inflammatory bowel disease 
patients [184]. 
D6-defincient mice were also subjected to a model of antigen induced disease, 
showing D6 as controller of chemokines and inflammation also in the lung [185]. In a model 
of intranasal injection of low doses of Mycobacterium tuberculosis D6
-/-
 mice resulted in 
dramatic local and systemic inflammation which exerts in mice death [186].  
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Finally, a recent work demonstrated D6 to be up-regulated in F4/80
high
 peritoneal 
macrophages during resolution of peritonitis[174] and in alveolar macrophages of COPD 
patients, indicating a possible role of D6 in promoting immune response [176]. 
 
1.4.1.2.3. D6 and cancer 
Inflammatory chemokines have been demonstrated to affect different steps of tumor 
development and progression [187] and D6, due to its important role in controlling the 
inflammation, has been subjected to different cancer models and in particular in 
inflammation-driven tumorigenesis (Figure 1.15). Indeed, D6
-/-
 mice in phorbol ester-induced 
skin tumorigenesis model and in an azoxymethane/sodium dodecylsulphate model of colon 
cancers resulted to be more susceptible than wt mice, caused by excessive inflammation and 
leukocyte infiltration. Moreover, Nibbs et al reported that in a mouse strain susceptible for 
papilloma formation D6 transgenic expression was protective, suggesting that D6 scavenger 
activity exerts in tumor suppression [188]. 
D6 expression has been reported in different tumors, including large granular 
lymphocytes leukemia cells[189], malignant vascular tumors [170] and breast cancers [190]. 
In particular, in human breast carcinoma D6 expression is regulated by different cytokines, 
like IL-1 and TNFα and inversely correlated with lymph node metastasis and clinical disease 
stage, whereas positively correlates with disease-free survival rate. Interestingly, in vivo and 
in vitro experiments confirmed that D6 plays an inhibitory role in tumor biology, in fact D6-
expressing breast cancer cell lines, injected in vivo, are associated to decreased 
inflammatory chemokine levels, decreased vessel density and TAM infiltration at tumor site 
[190]. 
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1.4.1.2.4. D6 in immune response 
D6, in two different model of disease, has been reported to play a role in the 
development of specific immune response (Figure 1.15). Firstly, in experimental 
autoimmune encephalomyelitis (EAE) induced by myelin oligodendroglial glycoprotein 
(MOG) peptide 35–55 administration in CFA, the absence of D6 causes aberrant 
inflammatory response associated to CD11c+ DCs accumulation in inflamed skin. The 
retention of DCs at the skin consequently produced a poor priming of encephalitogenic T 
cells and their decreased proliferation and IFNγ production. The poor T cell response 
resulted in protection of D6
-/-
 mice from encephalomyelitis [191]. Secondly, D6-deficient 
mice were investigated in a model of graft versus host disease (GvHD) where D6
-/-
 mice 
display a partial protection. Here the protection was caused by the accumulation of myeloid 
derived suppressor cells (MDSC), in particular of Ly6C
high
 monocytes in secondary lymphoid 
organs, which exhibit an enhanced immunosuppressive activity and so inhibit the 
development of adaptive immune responses, partially protecting mice from the 
development of GvHD [177]. 
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Figure 1.15: D6 in vivo activity. D6 is an important regulator for orchestration of the immune 
response by containing the local inflammatory response and controlling the migration to secondary 
lymphoid organs of DC and a subset of myeloid population with immunosuppressive properties. 
These activities have been demonstrated by the use of D6-deficient mice in different disease models, 
here subdivided in two classes: inflammatory and tumor models (on the left) and models involving 
specific immune response (on the right) [166]. 
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1.5. Chemokines and cancer  
Chemokines and chemokine receptors are key players in several stages of tumor 
progression, in particular in leukocyte recruitment at tumor site, but also in promoting 
angiogenesis and metastatization [192]. Different animal models confirmed their important 
function in crosstalk between tumor cells, leukocytes and tumor surrounding stromal cells 
(Figure 1.16). 
 
1.5.1. Chemokines and tumor infiltrating leukocytes 
A common feature of cancer is the infiltration of inflammatory leukocytes at tumor 
site, which is largely mediated by chemokines produced by neoplastic cells, stromal cells or 
even leukocytes themselves. Tumor infiltrating leukocytes, depending on tumor model, can 
be different and they would be recruited by corresponding chemokines. For example 
monocytes and macrophages have been demonstrated to be mainly recruited by CCL2 and 
CCL5 [59, 193, 194] in several murine model of tumors, such as breast cancer [195, 196], 
melanoma [197] esophageal carcinoma [198], colon cancer [199], prostate carcinoma [120] 
and pancreas tumor[120, 126, 147, 200, 201]. Moreover, in human tumors these two CC 
inflammatory chemokines have been correlated with TAM number, lymph node 
metastatization and poor prognosis [195, 196, 202]. Furthermore, high numbers of 
neutrophils infiltrating the tumor have been associated to overexpression of ELR+ CXC 
chemokines, in particular of CXCL8, and to negative outcomes [203]. Others CXC chemokines 
are correlated to neutrophil recruitment at tumor site: CXCL1 has been detected in gastric 
and colon carcinoma [204] and malignant melanoma [205]; CXCL5 is expressed by non-small 
cell lung cancer [206]; CXCL6 by gastrointestinal tumors [207]. Cancer cell lines over-
expressing CXCL8 display an increased PMN infiltration and a reduced growth when injected 
in mice [208], suggesting that PMN may have a protective role, but, on the contrary, in 
human tumor biopsies the presence of PMN has been correlated with poor prognosis [209-
211]. The major chemoattractant of dendritic cells is CCL20, which has been reported to be 
expressed by several tumors strongly infiltrated by DCs, including pancreatic, renal, breast 
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and papillary thyroid carcinoma [212, 213]. Other major attractants of immature DC include 
CCL5 in papillary thyroid carcinoma [214], CXCL12 in ovarian carcinoma [215] and CCL19 in 
breast carcinoma [216]. Tumors can contain variable numbers of tumor-infiltrating 
lymphocytes (TIL). In some tumors, in particular in colon carcinoma, the presence of TIL is a 
strong predictor of a positive outcome [217-219]. On the contrary in other tumors, like 
melanoma, the protective role of TIL is compromised by the high proportion of T regulatory 
cells (Treg) that down-regulate the activation and proliferation of tumor-reactive 
lymphocytes [220]. TILs are manly chemoattracted at tumor site by CXCL9 and CXCL10 
through their interaction with CXCR3, and evidences in human gastric and colon-rectal 
carcinoma defined that their expression correlates with a good prognosis [221, 222]. On the 
other hand, high levels of CCL17 and CCL20 have been associated with poor prognosis in 
breast [223, 224], ovarian [225], prostate [226] and gastric carcinoma [227] because they 
have been found to recruit CCR4+ Treg and polarized Th2 cells, which support tumor 
progression. 
 
1.5.2. Chemokines and angiogenesis  
CXC chemokines on the basis of the tri-peptide Glu-Leu-Arg (ELR) at the N-terminal 
domain can be divided in two main categories: ELR+ and ELR- CXC chemokines. The first ones 
are angiogenic whereas the other ones are angiostatic as assessed by their effects on 
endothelial cell proliferation and chemotaxis in vitro and in animal models, such as rat 
cornea and tumor regression in vivo [95, 228]. Angiogenic CXC chemokines, like CXCL5 and 
CXCL8, promote the migration and proliferation of endothelial cells, acting on CXCR1 and 
CXCR2, which are expressed by endothelial cells. They stimulate endothelial cell proliferation 
and inhibition of apoptosis. Moreover, engagement of CXCR2 induced up-regulation of 
metallo-proteases such as MMP-2 and MMP-9 that are involved in extracellular matrix 
degradation and in releasing of other angiogenic factors such as VEGF and FGF2 [229]. 
Another important angiogenic chemokine is CXCL12, whose receptor CXCR4 is expressed by 
endothelial cells and its activation supports endothelial cell migration and proliferation, and 
recruitment at tumor site of endothelial precursors [230]. Conversely, CXCL4,CXCL9, CXCL10 
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and CXCL11, via CXCR3 activation, are potent angiostatic factors, inhibiting 
neovascularization and endothelial cell proliferation [231]. 
 
1.5.3. Chemokines and metastasis 
Chemokines and chemokine receptors also play a fundamental role in metastasis. In 
this context the most studied chemokine receptor is CXCR4 together with its ligand CXCL12, 
which has been found to be up-regulated in several tumors and to be expressed also on 
cancer stem cells (CSC). In fact, CXCR4+ CSC have been isolated from glioblastoma [232] and 
pancreas carcinoma [233]. CXCR4 is also associated with lymph node metastasis in oral 
squamous cell carcinoma, human nasopharyngeal carcinoma, pancreatic cancer, non-small 
lung cancer, human colorectal cancer, and human breast cancer. Other chemokine receptors 
have been correlated with tumor metastasis, for example CXCR1, CXCR5 and CCR7. In 
particular, CCR7 is up-regulated in several tumor models, leading cell dissemination through 
lymphatic vessels into lymph nodes. Indeed, it is now considered a potential marker for 
metastasis prediction in breast and colon-rectal cancer [234]. 
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Figure 1.16: – Chemokine and chemokine receptor in cancer. Chemokines and chemokine receptors 
affect several step of tumor progression, including survival and proliferation of tumor cells, 
recruitment of leukocytes at tumor site, angiogenesis, migration and metastatization of tumor cells 
[192]. 
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1.6. Kaposi’s sarcoma 
Kaposi’s Sarcoma (KS) is the most common malignancy associated with HIV infection 
[235] and the most common tumor in African men [236]. It is a highly vascularized tumor 
holding endothelial lymphatic origin [237, 238] and characterized by extravasation of 
erythrocytes, infiltration of inflammatory cells and neoangiogenesis [239]. Tumor cells have 
a characteristic spindle shape, are poorly differentiated and highly proliferative [240]. In 
1994, a novel viral DNA sequence in KS biopsies was discovered and named KS-associated 
herpes virus (KSHV) but it was later classified as human herpes virus 8 (HHV-8) [241]. 
Successive studies found that Kaposi’s sarcoma (KS) is directly caused by infection of LEC by 
the human herpes virus 8 (HHV8). KS tumor cells are considered to be derived from the LEC 
lineage and expresses several LEC markers, including VEGFR3, LYVE-1, and PROX1 [242]. 
Interestingly, it has been shown that KS can also derive from HHV8-infected blood vascular 
cells undergoing a lymphatic reprogramming which creates a more favorable 
microenvironment for the tumor growth [243].  
 
1.6.1. Epidemiology 
Despite the fact that HHV8 infection is widespread, KS occurs only sporadically in 
immunocompetent individuals whereas it is relatively common in immunocompromized 
patients, in particular in HIV patients or transplanted patients treated with 
immunosuppressive drugs. KS can be classified in four classes: the indolent form affecting 
older men was referred to as “classical” or “sporadic”; more aggressive cases from 
subequatorial Africa are named “endemic”; KS associated to immunosuppression treatment 
of transplanted patients are defined “iatrogenic” and finally KS derived from HIV infection is 
called “epidemic” or “AIDS-related” KS. 
Classical KS is usually characterized by slow-progressing skin lesions and limited 
dissemination ability, on the contrary in immunocompromized patients it displays a more 
aggressive phenotype, with widespread diffusion on the skin, frequent involvement of 
visceral organs, and life-threatening complications [244]. Moreover, HIV-infected individuals 
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show a risk to develop KS a thousand times higher than general population [245-247] but 
luckily KS has been shown to regress during HAART treatment [248-251]. This is 
epidemiologically highlighted by strong decreases of KS incidence in AIDS patients since the 
use of HAART became widespread [252, 253]. It is also reported that incidence of KS in 
patients treated with immunosuppressors because of organ transplantation is 500-1000 
times greater than in the general population [254], indeed 0.5-5% of organ transplant 
recipients develop Kaposi’s Sarcoma, depending on their geographical origin and the type of 
organ received (Figure 1.17) [255]. Little information is available on the risk of KS among 
immunocompetent HHV-8-positive individuals. HHV-8 is known to be transmitted by blood 
or blood products [256] but also virus transmission among family members, associated with 
close contact and crowding, has been reported [257-260]. There is little evidence of the 
vertical transmission of HHV-8 during pregnancy. Among homosexual men, there is 
consensus that virus transmission is sexual, whereas among heterosexuals correlates with 
sexual transmission have not been consistently established. As current therapeutic options 
are only palliative, KS is also a leading cause of morbidity and mortality in AIDS patients [261, 
262].  
 
 
Figure 1.17: –. Geographical prevalence of KS. Standardized incidence of Kaposi’s sarcoma (KS) in 
males obtained from the International Agency for Research on Cancer Incidence in Five Continents 
publication [261]. 
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1.6.2. Clinical features 
KS lesions appear as multiple foci highly heterogeneous in their composition 
depending on the disease stage. The first lesions detectable in the dermis, called patch 
lesions, are composed by few HHV8-infected spindle cells, an abundant inflammatory 
infiltrate mainly composed by T and B lymphocytes and monocytes, and a prominent 
angiogenic process. Then lesions progress to the plaque stage, characterized by solid, 
edematous, and violaceous in color lesions, and finally to maculo-nodular lesions, with 
abundant abnormal leaky vessels with edema and red blood cells extravasation and a 
predominance of spindle cells [263]. At the clinical level, KS lesions are classified in four 
stages, such as stage I: maculo-nodular lesions; stage II: infiltrative; stage III: florid; stage IV: 
disseminated. As for still unknown reasons lesions at the same stage show highly variable 
progression rate, they are further subdivided retrospectively according to the speed of 
disease evolution in A: slow progressive lesions; B: rapid progressive lesions [264]. 
Usually, the disease appear as violaceous skin lesions and it can then precede with 
oral, visceral or nodal involvement but lesions are typically multifocal and do not have a 
predictable order of progression. They can be solitary modules or can form plaques or even 
occur in clusters.  
In many cases, edema is associated with KS either locally or at distal site. It is thought 
to be caused by mechanical obstruction of draining lymphatic vessels and also supported by 
production of permeability factors in KS lesions, as VEGF-A. Moreover, new vessels formed 
inside KS lesions are leaky and cause extravasation of cells and plasma proteins into 
surroundings tissues, improving edema formation. 
Other organs can be involved in the disease, for example one of the most affected 
tissues is the gastro-intestinal tract that can be so damaged to result in massive bleeding. 
Also pulmonary involvement is frequent and based on localization can turn out in bronchial 
irritation, pleural effusions, hemoptysis or in the more severe cases the parenchyma can be 
involved with a consequent life-threatening respiratory problems and high mortality. 
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1.6.3. Pathogenesis 
1.6.3.1. HHV8 as oncogene 
Kaposi’s sarcoma is a tumor caused by infection of lymphatic endothelial cells by KS-
associated herpes virus (KSHV), now re-named human herpes virus 8 (HHV-8). Kaposi tumor 
spindle cells express markers typical of lymphatic vessels, as VEGFR-3, podoplanin and PROX-
1 [242]. Moreover, it has been demonstrated that HHV-8 infection of endothelial vascular 
cells induces their reprogramming towards lymphatic phenotype, up-regulating lymphatic 
specific genes like PROX-1 and LYVE-1 and down-regulating vascular endothelial genes [242]. 
HHV-8 is thought to be necessary to develop KS in all its form, but it also causes 
primary effusion lymphoma (PEL) and multicentric Castelman’s disease. It belongs to the 
family of γ-herpes virus and its genome is composed by a double-stranded DNA whose size 
can range from 140 to 170 kb [265, 266]. HHV-8 genome contains several open reading 
frames (ORF), named from K1 to K5 according to their location into the viral genome, and 
several viral genes, mostly copied from host genome (Figure 1.18) [267]. 
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Figure 1.18: – KSHV genome. KSHV or HHV-8 encodes 87 open reading frames (ORF), many of these 
encode cellular orthologous, in particular cytokines, chemokines and a viral GPCR (ORF74). Putative 
latent transcripts are indicated in green, and cellular orthologous in yellow [261].  
 
HHV-8 lifecycle is composed by two phases: latent and lytic phase. During the first 
one, viral genome is circularized and not integrated in host chromosomes and no viral genes 
are transcribed [268]. On the contrary, during the lytic phase the viral genome is linearized 
and viral genes are transduced in proteins. It is thought that some viral proteins show 
oncogenic properties whereas others are growth or angiogenic factors, essential for tumor 
development. One of these proteins is latency-associated nuclear antigen (LANA) which is 
able to perturb host cellular pathway. In particular, LANA binds p53 inhibiting its ability to 
induce gene transcription and apoptosis [269] and can inactivate the tumor suppressor 
retinoblastoma (Rb) protein (Figure 1.19). 
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Figure 1.19: – Proposed mechanism of HHV-8-induced sarcoma. In lytic cells HHV-8 expresses early 
lytic genes like vGPCR and vIL-6 subverting host signaling pathway, activating oncogenes, for example 
K-RAS and consequently MAPKs [261]. 
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1.6.3.2. HHV-8: tumor growth and subversion of the immune responses 
KS growth has been demonstrated to be associated with lytic HHV-8 markers that 
lead to abnormal production of inflammatory cytokines and chemokines, leading to 
immune-dysregulation [270]. Spindle cells do not display some characteristics of 
transformed cells, being euploid and not clonal, and with a growth potential in vitro and in 
vivo largely dependent by the autocrine/paracrine activity of angiogenic and inflammatory 
cytokines, including VEGF-A, bFGF2, IL-6, and IL-1β [244, 271]. It has been proposed that 
spindle cells produce cytokines that recruit leukocytes and vessels, which in turn produce 
growth factors required for their proliferation [263, 272, 273]. Consistent with this, KS 
lesions often occur at inflammatory sites or in scaring tissues, a condition known as Koebner 
phenomenon, and in patients with the Immune Reconstitution Inflammatory Syndrome 
[274].  
Among inflammatory mediators, chemokines have been extensively investigated in 
KS pathogenesis because HHV8 has hijacked the chemokine system in several ways [275]. 
HHV8 through ORF74 encodes a constitutively active GPCR (vGPCR) which shares similarities 
with CXCR1 and CXCR2 recognizing both angiostatic ELR- and angiogenic ELR+ CXC 
chemokines and acts as a transforming receptor in transgenic mice [276]. vGPCR displays a 
constitutive signaling activity, leading to phosphorylation of PI3-kinase and MAPK ERK1/2 
and p38 [277]. HHV-8 is also able to produce three CC chemokines (vMIP-I, -II, and -III) which 
interact with CCR3, CCR8 and CCR4, receptors expressed at high levels in Th2 and Treg cells 
[278, 279]. These viral inflammatory CC chemokines represent a strategy to subvert and 
divert effective antiviral and antitumor immunity. In addition, HHV8-infected endothelial 
cells display increased production of several chemokines, including CCL2, CCL5, CXCL8, and 
CXCL16 [280, 281]. 
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2. Aim 
 
This thesis is focused on the role in tumor progression of the inflammatory 
chemokine CCL2 and its two receptors: the canonical CCR2 and the atypical chemokine 
receptor D6.  
In the first part the role of D6 in Kaposi’s sarcoma biology has been investigated by 
using a Kaposi’s sarcoma cell line overexpressing D6 injected in nude mice. Moreover D6 
expression was also analyzed in human KS lesion confirming in vivo evidences. 
In the second part, we investigated the possible role of CCR2 in tumor associated 
macrophage (TAM) polarization and its abilities in shaping tumor microenvironment and 
supporting tumor progression. 
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3. Materials and methods 
 
3.1. Part 1 
 
Immunohistochemistry 
Formalin-fixed paraffin-embedded cutaneous nodular KS lesions from HIV-
seropositive and -seronegative cases were obtained from Luigi Sacco Hospital and Ospedale 
Maggiore Policlinico, Milan, Italy, respectively. Cutaneous nodular KS lesions from HIV-
seronegative patients were classified according to a staging system [264] comprising 4 
clinical stages (stage I: maculo-nodular lesions; stage II: infiltrative; stage III: florid; stage IV: 
disseminated), each further divided according to the speed of disease evolution (A: slow and 
B: rapid). Ethics approval for D6 expression analysis was obtained from the local Institutional 
Review Committee and a signed informed consent was obtained from all participants. 
Sections were incubated with rat anti human D6 monoclonal antibody (clone 196124, 1:100 
dilution; R&D Systems) and mouse anti human KSHV Orf73 monoclonal antibody (1:100 
dilution; Dako). For murine tumors, frozen sections were incubated with rat anti mouse 
CD31 monoclonal antibody (1:100 dilution; obtained as described in ref. [282]. 
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Cell culture and transfection 
The KS-IMM cell line, originally isolated from a KS occurring in a kidney transplanted 
immunosuppressed patient [283], was grown in DMEM (Lonza) with 10% FCS. KS-IMM cells 
were transfected with the hD6/pEFGP-N1 or empty pEFGP-N1 expression plasmids by using 
Lipofectamine 2000 (Invitrogen) and selected using 400 µg/ml G418 (Invitrogen). For growth 
curve, KS-IMM cells were seeded in 6-well plates (5 x 10
4
 cells/well) and grown under normal 
conditions for 1-4 days. Every day, cells were harvested with trypsin from three wells for 
group, diluted in Trypan blue to assess viability and counted. For preparation of cell culture 
supernatant, KS-IMM cells (1 x 10
6
 cells) were cultured in 75 cm
2
 flasks with complete 
medium. After 48 h, culture medium was discarded and fresh medium without G418 
resistance was added to the flask for 24 h. Supernatant was collected and centrifuged. 
Immunofluorescence microscopic analysis 
KS-IMM cells (10
5
) were seeded in 24-well plates and grown at 37°C for 18 h. Cells 
were fixed with 4% paraformaldehyde, then incubated with DAPI. High-resolution images 
(1024 x 1024 pixels) were acquired sequentially with a 60x/1.4 NA Plan-Apochromat oil 
immersion objective was used with a FV1000 laser scanning confocal microscope (Olympus). 
Differential interference contrast (Nomarski technique) was also used. Images were 
assembled and cropped using the Photoshop software (Adobe Systems). 
 
Reverse-transcriptase polymerase chain reaction 
Total RNA was extracted from cell pellets using the TRIZOL reagent (Invitrogen). The 
reverse transcriptase polymerase chain reaction (RT-PCR) was performed using a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer’s instructions. Primers for human D6 (forward: 5’-GGGTTTCTCCTTCCACTCCT-
3’, reverse: 5’-TATTCCCCACATCCTCCTTG-3’) and human β-actin (forward: 5’-
GCTCGTCGTCGACAACGGCT-3’, reverse 5’-CAAACATGATCTGGGTCATCTTCTCT-3’). TaqMan 
real-time RT-PCR (probes of Applied Biosystems) was used to detect D6 RNA in KS-IMM 
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seeded in DMEM 1%FCS overnight and stimulated for 8 or 24 h with UO126 (10 µM; 
Calbiochem) and PLX4032 (1µM; Selleckchem) 
 
Chemokine scavenging assay 
KS-IMM transfectants were plated the day before the experiment in 96-well (3 x 10
4
 
cells/well), then incubated with 10 ng/ml of CCL3L1 (R&D Systems) for increasing times. The 
supernatant was collected and chemokine concentration was evaluated by sandwich ELISA 
(R&D Systems). 
 
Animals and treatment 
WT and CCR2
-/-
 C57/Bl6 mice and nude CD-1 mice were purchased from Jackson 
Laboratories and Charles River Italia (Calco), respectively. Animals were housed in pathogen-
free conditions, and used at 8-12 weeks of age. Mice were injected s.c. in the flank with 5 x 
10
6
 KS-IMM cells mixed with liquid matrigel (BD Biosciences). The two major tumor 
diameters were measured every 2-3 days with a caliper and tumor volume was estimate 
applying the formula (d1xd2
2
)/2. To deplete neutrophils in vivo, the purified anti-Ly6G rat 
mAb (clone 1A8; BioXCell) was administered to mice (i.p.; 0.2 mg) 1 day prior to KS-IMM 
inoculation and every 3 days thereafter. Control animals received purified whole rat IgG2a 
(BioXCell). Pharmacological inhibition of CCR2 was achieved treating mice daily with 2 mg/kg 
RS-504393 (Santa Cruz Biotechnology) by oral gavage from the day of KS-IMM injection until 
the day animals were sacrificed. In some experiments, BMDM (10 ng/ml mM-CSF) generated 
from WT and CCR2
-/-
 C57/Bl6 mice were mixed in liquid matrigel at 1:2 ratio with KS-IMM 
cells and s.c. injected. Animal housing and procedures were in accordance with national (D.L. 
N.116, reviewed and approved Gazzetta Ufficiale della Repubblica Italiana, supplement 40, 
18-2-1992) and international law and policies (European Economic Community Council, 
1987, Directive 86/609, Official Journal of European Community L 358.1; and Institute of 
Laboratory Animal Resources, Committee on Life Sciences, National Research Council, 1996, 
Guide for the Care and Use of Laboratory Animals). Animal procedures were also reviewed 
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and approved by the Institutional Ethical Committee at Humanitas Clinical and Research 
Center. 
 
Bone marrow-derived macrophages (BMDM) 
BM cells were obtained from femurs of 8 weeks old male WT and CCR2
-/-
 C57/Bl6 
mice and plated with DMEM with 5% FCS for 4 h at 37°C. Non-adherent cells were recovered 
and plated at 3 x 10
5
 cells/well in 24 well ultra-low attachment plates (Corning Costar) and 
cultured for 7 days in the presence of 25% conditioned media from D6
-
KS-IMM or D6
+
KS-
IMM cultures or with 20 ng/ml mM-CSF (Miltenyi) added every two days. When indicated 
indomethacin (Sigma) was added to cultures at 10 µM from day 0. After 7 days, cells were 
detached with cold Accutase (Millipore). 
 
FACS analysis and sorting 
Flow cytometry was performed using FACSCanto II flow cytometer and FACSDiva 
6.1.1 software (BD Biosciences) or Flowjo (Treestar). KS-IMM cells were sorted for EGFP 
expression by using a FACS Aria flow cytometer (BD Biosciences). For tumor infiltrate 
analysis, tumor explants were harvested at the indicated time points, minced and incubated 
in DMEM with 1% FCS plus collagenase IV (Sigma-Aldrich Chemicals) for 30 min at 37ºC, then 
passed through a 70 µm nylon mesh filter (BD Falcon). Erythrocytes were lysed with ACK 
buffer. Cells were stained with anti-mouse: CD45-PercP, CD11b-APC, Ly6G-PE, Ly6C-FITC, I-
A/I-E-Biotin, anti-CD206-Biotin (BD Biosciences), and F4/80 (Serotec). Dead cells were 
excluded by LIVE/DEAD Fixable Cell Stain Kit (Invitrogen). The absolute number was 
determined using TruCount beads (BD Biosciences) according to the manufacturer’s 
instructions. 
 
Cytokine levels 
KS-IMM cells were seeded into 24-well microplates (9 x 10
5
 cells/well) and grown 
under normal conditions for 24 h. The medium was replaced by DMEM with 1% FCS, and in a 
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particular experiment 10 ng/ml hIL-1β (R&D Systems) were added. Supernatants were 
collected after 24 h and hCCL2, hIL-6 and hVEGF-A were measured using sandwich ELISA 
(R&D Systems). mVEGF-A was measured in tumor lysates and BMDM supernatants using 
ELISA test (R&D Systems) and murine chemokines using bio-plex protein assay (Bio-Rad). 
 
Western blot 
0.7 x 10
6
 cells were treated as indicated and lysed with a buffer containing 50 mM 
Tris-HCl (pH 8), 150 mM NaCl, 5 mM EDTA, 1.5 mM MgCl2, 10% glycerol, 1% triton X-100, and 
protease/phosphatase inhibitors. The lysates were electrophoresed and immunoblotted 
with the antibody rabbit anti-human ph-ERK1/2 (Cell Signaling) using standards conditions. 
Chemiluminescence was acquired by ChemiDoc XRS Imaging System, densitometric analysis 
was performed by Image Lab software (Bio-Rad) and protein band intensity was calculated 
by normalization over α-tubulin band intensity. 
 
Statistical analysis 
Data were compared using unpaired Student's t test. Immunohistochemical data 
were analyzed by the two-tailed unpaired t test with Welch's correction (GraphPad Prism4 
software). *, P<0.05; **, P<0.005; ***, P<0.0005. Linear regression analysis was obtained 
using Prism4 software. 
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3.2. Part 2 
 
Bone marrow-derived macrophages (BMDM) 
BM cells were obtained from femurs of 8 weeks old male WT and CCR2
-/-
 C57/Bl6 
mice and plated in IMDM with 10% FCS overnight at 37°C. Non-adherent cells were 
resuspended at 5 x 10
6
 cells/dish in complete bone marrow macrophage medium (IMDM, 
10% FCS, 150 μM MTG, 1%P/S, 1%Glut, 10 ng/mL M-CSF) in low attachment culture dish 
(Corning Costar) and cultured for 7 days replacing medium at day 3. To prepare BMDM to 
further stimulations, cells were detached with 2mL of Accutase and replate at the 
concentration of 0.5 x10
6
 cells/mL in complete bone marrow macrophage medium without 
M-CSF in multiwell 6 or 24 wells low attachment (500uL/well). After overnight culture 
BMDM were stimulated with 100 ng/mL LPS (Sigma) plus mIFNγ (Peprotech) 20ng/mL or 100 
ng/mL LPS alone or 20 ng/mL mIL-4 (Peprotech) for indicated time points. 
 
Human monocytes from buffy coat 
Human monocytes were obtained from healthy donor buffy coats by 2-step gradient 
centrifugation using Ficoll (Biochrom) and Percoll (Amersham). 2 x 10
6 
cells were plated in 6 
wells in RPMI 1640 medium (Lonza) without FCS for 20 min. Non-adherent cells were 
discarded, and cells were incubated in RPMI 1640 medium supplemented with 10% FCS 
overnight. Monocyte polarization was obtained by removing the culture medium and 
culturing cells in RPMI 1640 medium supplemented with 1% FCS and 100 ng/mL of LPS 
(Sigma) for indicated time points. 
 
FACS analysis  
Flow cytometry was performed using FACSCanto II flow cytometer, LRSFortessa cell 
analyzer and FACSDiva 6.1.1 software (BD Biosciences). BMDM were stained on membrane 
surface with anti-mouse: CD11b-APC, Ly6C-FITC, I-A/I-E-Biotin, CD206-Biotin, Streptavidin-
PercP (BD Biosciences), and F4/80 PE (Serotec). Intracellular staining of Relmα (Peprotech) 
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was perform with BD Cytofix/Cytoperm™ Kit (BD Biosciences). Annexin V/7AAD staining was 
performed on human monocytes according to the manufacturer’s instructions (Annexin V: 
PE Apoptosis Detection Kit I - BD Biosciences). For tumor infiltrate analysis, tumor explants 
were harvested at the indicated time points, minced and incubated in DMEM with 1% FCS 
plus collagenase IV (Sigma-Aldrich Chemicals) for 30 min at 37ºC, then passed through a 70 
µm nylon mesh filter (BD Falcon). Erythrocytes were lysed with ACK buffer. Dead cells were 
excluded by LIVE/DEAD Fixable Cell Stain Kit (Invitrogen). Tumor macrophages and PMN 
were stained with anti-mouse: CD45-PercP, CD11b-PE-CF594, Ly6G-PE, Ly6C-BV605, CD206-
FITC (BD Biosciences), I-A/I-E-AlexaFluor700 (eBioscience), F4/80- PacificBlue (Serotec); 
tumor lymphocytes with CD19-PacificBlue, CD3-FITC, CD4-PeCy7(BD Biosciences), CD25-PE, 
Foxp3-APC (eBioscence). The absolute number was determined using TruCount beads (BD 
Biosciences) according to the manufacturer’s instructions. 
 
Cytokine levels 
Supernatants were collected from BMDM culture at indicated time points and mIL-10 
and mVEGF-A were measured using sandwich ELISA (R&D Systems). 
 
Reverse transcription (RT) and qPCR  
Total RNA was extracted from cell pellets using miRNeasy Mini Kit (Qiagen). The 
reverse transcriptase polymerase chain reaction (RT-PCR) was performed using a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems). To measure iNOS2, Arg-1 and 
IL-12p40 expression in BMDM, SYBR Green real-time PCR was used. Primers for murine 
iNOS2 (forward: 5’-gccaccaacaatggcaaca-3’, reverse: 5’-cgtaccggatgagctgtgaatt-3’), murine 
Arg-1 (forward: 5’-cagaagaatggaagagtcag-3’, reverse 5’-cagatatgcagggagtcacc-3’) and murine 
IL-12p40 (forward: 5’-ggaagcacggcagcagaata-3’, reverse 5’-aacttgagggagaagtaggaatgg-3’). 
 
Western blot 
1 x 10
6
 of WT and CCR2
-/-
 BMDM cells or human monocytes were treated as indicated 
and lysed with a buffer containing 50 mM Tris-HCl (pH 8), 150 mM NaCl, 5 mM EDTA, 1.5 
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mM MgCl2, 10% glycerol, 1% triton X-100, and protease/phosphatase inhibitors. The lysates 
were electrophoresed and immunoblotted with the antibodies rabbit anti-human phospho-
NF-Kb p65, phospho-p38 MAPK and phospho-p44/42 MAPK using standards conditions. All 
antibodies were purchased from Cell Signaling. Chemiluminescence was acquired by 
ChemiDoc XRS Imaging System, densitometric analysis was performed by Image Lab 
software (Bio-Rad) and protein band intensity was calculated by normalization over α-
tubulin band intensity or total p38 MAPK.  
 
Animals and treatment 
WT and CCR2
-/-
 C57/Bl6 mice were purchased from Jackson Laboratories. Animals 
were housed in pathogen-free conditions, and used at 8-12 weeks of age. Animal housing 
and procedures were in accordance with national (D.L. N.116, reviewed and approved 
Gazzetta Ufficiale della Repubblica Italiana, supplement 40, 18-2-1992) and international law 
and policies (European Economic Community Council, 1987, Directive 86/609, Official 
Journal of European Community L 358.1; and Institute of Laboratory Animal Resources, 
Committee on Life Sciences, National Research Council, 1996, Guide for the Care and Use of 
Laboratory Animals). Animal procedures were also reviewed and approved by the 
Institutional Ethical Committee at Humanitas Clinical and Research Center. 
WT mice were s.c. injected with BMDM generated from WT and CCR2
-/-
 C57/Bl6 mice 
mixed in liquid matrigel (BD Biosciences) at 1:1 ratio with 3LL cells (Lewis lung carcinoma cell 
line). The two major tumor diameters were measured every 2-3 days with a caliper and 
tumor volume was estimate applying the formula (d1xd2
2
)/2. 
 
Statistical analysis 
Data were compared using unpaired Student's t test of Prism4 software. *, P<0.05; 
**, P<0.005; ***, P<0.0005.  
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4. Results 
 
4.1. D6 inhibits CCR2+ macrophage-dependent angiogenic switch 
in Kaposi’s sarcoma 
 
4.1.1. D6 is expressed in KS lesions 
The atypical chemokine receptor D6 is known to be expressed by the afferent 
lymphatic endothelium and in particular by the lymphatic endothelial cells (LEC) [170]. Due 
to the fact that this cells are considered the precursors of the KS spindle cells [242], D6 
expression in lesions of KS patients was investigated by immunohistochemistry. A broad 
expression of the receptor was detected in Kaposi’s lesions and in particular in tumor spindle 
cells that were also positive for the HHV8-encoded nuclear antigen LANA-1 (Figure 3.1A). 
Moreover D6 expression was evident on membrane surface and in intracellular 
compartments, as previous reported in transfectant cells [168]. Analyzing lesions from HIV-
seronegative or seropositive patients, a significant increased expression of D6 was observed 
in indolent cutaneous nodular lesions of HIV- patients as compared to aggressive lesions of 
HIV+ ones (Figure 3.1B). Furthermore lesions from seronegative patients at the maculo-
nodular stage (stage I) were analyzed and classified, based on the speed of the disease 
progression, in slow (A) and rapid (B) progressive [264]. Upon this classification, D6 
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expression resulted to be significantly higher in patients who showed a slow disease 
progression rate (stage IA) as compared to those characterized by a rapid progression rate 
(stage IB) (Figure 3.1C). 
 
 
Figure 3.1 - D6 expression in human KS lesions and KS-associated HHV8+ spindle cells. (A) 
Representative immunohistochemical analysis of a cutaneous KS lesion from a HIV-seronegative 
patient stained for human D6 (brown) and viral antigen LANA-1 (blue). KS spindle cells are indicated 
by arrows. Magnification 10x (left panel) and 40x (right panel). (B) D6 immunohistochemical analysis 
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in cutaneous maculo-nodular KS lesions from HIV-seropositive and seronegative patients (n=22) and 
from HIV-seronegative patients affected by disease with slow (stage IA) and rapid (stage IB) 
progression rate (panel C, n=21). Representative panels of D6 staining are shown on the right 
(magnification 20x). Scatter plots report mean values ± SEM from five random fields evaluated for 
number of positive cells using a semiquantitative scale (0: no positive cells; 1: 0÷25% positive cells; 2: 
25÷75% positive cells; 3: >75% positive cells). *p<0.05, ***p<0.0005. 
 
4.1.2. Generation and characterization of D6+ and D6- KS-IMM transfectants 
To gain insight the role of D6 in KS, we used the human cell line KS-IMM, originally 
derived from a biopsy of an iatrogenic KS. It is a not-subclonal population which have a 
Kaposi’s Sarcoma characteristic spindle shape and is able to grow in nude mice as highly 
vascularized tumors closely resembling human KS lesions [283].  
KS-IMM were analyzed by RT-PCR for the expression of D6 and other chemokine 
receptors. They resulted to be negative for D6 but also for CCR2 CCR4 and CCR5, receptors 
that share some ligand with D6. The lack of D6 may be explained by the fact that often 
lymphatic endothelial cells can lose expression of specific markers when cultured in vitro, as 
already demonstrated for the lymphatic endothelial cell line MELC [284]. Therefore, in order 
to obtain a cell population expressing D6, cells were transfected with the empty pEGFP-N1 
vector or with D6-pEGFP-N1. Three independent populations with each vector were 
achieved and were called D6-KS or D6+KS respectively. The over-expression of the receptor 
was confirmed by RT-PCR (Figure 3.2 A), FACS (Figure 3.2 B) and confocal analysis (Figure 3.2 
C). All the transfectants showed expression of GFP and human adhesion molecule ICAM-1, 
whereas only D6+KS cells expressed D6. However, by flow cytometry only 25% of D6+KS 
resulted to be positive for D6 staining, suggesting an intracellular compartmentalization of 
the receptor. In fact fluorescence microscopy displayed the receptor to be mainly stored in 
intracellular perinuclear compartments consistent with the distribution of D6 observed in KS 
spindle cells (Figure 3.2 C) and other D6 transfectants [169]. In order to confirm the 
functional activity of the receptor, cells were incubated with exogenusly provided CCL3L1, 
one of the active ligand of D6 and, at different time points, supernatants were collected and 
measured by ELISA test. Only D6+KS were found to be able to degrade chemokines, showing 
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high scavenging activity at 6 hours (85 ± 5%) and 24 hours (97 ± 3%), establishing that the 
receptor is capable of its typical scavenger activity. Furthermore CCL2 autocrine production 
in basal conditions or after IL-1β stimulation [283] was reduced in the supernatant of D6 
expressing cells when compared to D6-KS (Figure 3.2 D) while no difference in IL-6 or VEGF-A 
amounts was found, consistent with D6 specificity for chemokines. Finally, in order to 
understand if D6 overexpression modified KS-IMM growth, cells were plated at the same 
concentration and counted for the following four days. The same growth rate of D6-KS and 
D6+KS cells was detected with a calculated duplication time of 23,5 ± 2,3 hours and 25,7 ± 
2,8, respectively (Figure 3.2 F). In conclusion, KS-IMM cells after transfection express a fully 
functional D6 scavenger receptor, which has an impact on the chemokine milieu but not on 
the production of other cytokines neither on cell growth in vitro. 
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Figure 3.2 - Characterization of D6+KS. (A) RT-PCR of D6 expression in a representative KS-IMM cell 
line transfected with D6-pEGFPN1 expression vector (D6+KS) and the corresponding control vector 
pEGFP-N1 (D6-KS). (B) FACS analysis of GFP, D6 and ICAM-I expression in a representative D6-KS 
(upper panel) and D6+KS transfectants (lower panel). (C)Confocal microscopy of a representative D6+ 
(lower panel) and D6- (upper panel) KS cells. (D) Hccl2 production by D6+ (black bar) and D6- (white 
bar) KS cells in homeostatic conditions or after IL-1β stimulation. (E) Human IL-6 and VEGF-A 
production by D6+ (black bar) and D6- (white bar) KS cells cultured in a medium containing low FCS 
(1%) for 24 h. (F) Kinetics of CCL3L1 scavenging in representative KS cell lines (KS-IMM wild-type ■, 
D6+KS ●,D6-KS ○). (G) Growth curve of KS cell lines (KS-IMM wild-type ■, D6+KS ●,D6-KS ○). Data are 
expressed as the percentage of seeded cells. In all panels data are the mean ± SEM of at least three 
independent experiments. **p<0.005,***p<0.0005 D6-KS versus D6+KS. 
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4.1.3. D6 expression restrains KS growth in vivo 
In order to investigate the in vivo role of D6 in KS biology, three independent 
populations of D6+KS and D6-KS were implanted in the flank region of CD-1 nude mice and 
tumor growth was measured with the caliper twice a week. The two groups of animals 
showed a comparable tumor uptake, growing in a similar way until day 19 after injection. 
However, from that time on D6-KS were significantly larger than D6+KS and, at the 
conclusion of the experiment, they were on average 2.77±1.28 times bigger than D6+KS. 
These results suggest that the expression of D6 did not influence tumor uptake but strongly 
reduce tumor growth (Figure 3.3). 
 
 
Figure 3.3 - D6 expression restrains KS tumor growth in vivo. Panels A and B report the growth rate 
of tumors generated in the flank of each CD-1 nude mouse injected with 5 x 106 D6-KS (n=23) or 
D6+KS (n=17) cells, respectively. Panel C shows average volumes ± SEM of tumors derived from 
D6+KS (■) and D6-KS (□). Representative tumor explants derived from D6-KS (upper) and D6+KS 
(lower) are shown on the side. ***p<0.0005. 
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4.1.4. Reduced levels of inflammatory chemokines in D6+KS tumors 
In order to identify the mechanism by which D6 overexpression at tumor site 
inhibited KS-IMM growth, tumor lysates from D6-KS and D6+KS were analyzed by ELISA for 
cytokine content. Inflammatory cytokines and chemokines are key elements in the 
pathogenesis of Kaposi’s Sarcoma, being an highly vascularized tumor characterized by an 
abundant inflammatory infiltrate, mainly composed by T and B lymphocytes and monocytes, 
and a prominent angiogenic process. Leukocytes and tumor cells produce many 
inflammatory cytokines, including IL-6, TNF-α, TNF-β, INF-γ, IL-1α and IL-1β, and angiogenic 
growth factors, for example VEGF, that acts in autocrine and paracrine manner promoting 
tumor progression. 
As expected, when compared to D6-KS lysates, D6+KS lysates contained lower 
amount of host-derived inflammatory chemokines mCCL2, mCCL5 and mCCL3, which are 
efficiently degraded by D6 (Figure 3.4 A, 3.4 B and 3.4 C, respectively). Very low 
concentrations of hCCL2 were detected (data not shown), indicating that the main source of 
chemokines in the system were infiltrating host cells rather than tumor cells, as reported for 
some human tumors [187]. 
 
Figure 3.4 - Increased inflammatory chemokine content in D6-negative tumors. mCCL2 (A), mCCL5 
(B), and mCCL3 (C), and were measured in homogenized tumors at day 14 after inoculation. Data are 
expressed as the mean concentration ± SEM of the chemokine levels normalized for the tumor 
volume (n= 4/each group). In all figures histograms represent the mean ± SEM of at least three 
independent experiments (n = 5 tumors/group) of D6+KS (black bar) or D6-KS (white bar). *p<0.05, 
**p<0.005. 
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4.1.5. D6 expression inhibits tumor growth by modulating leukocyte infiltrate 
As D6 expression influences the intratumoral chemokine milieu, tumors at different 
time points after inoculation were explanted and characterized for their cellular composition 
by flow cytometry analysis. Tumor masses were composed by about 50% of tumor cells, 
identified as FSC
high
, SSC
high
, EGFP+, CD45- cells while the remaining 50% of the tumor 
masses was represented by infiltrating leukocytes (EGFP-/CD45+) (Figure 3.5 A). D6+KS 
tumors displayed a significantly reduced number of both tumor cells and infiltrating 
leukocytes when compared to D6-KS tumors (Figure 3.5 B-C). Furthermore the expression of 
D6 not only had significant impact on the number of tumor cells and infiltrating leukocytes, 
but also qualitative effects on infiltrating leukocytes. In fact, in the absence of D6, KS tumors 
showed a significant increase in infiltrating neutrophils, identified as CD11b+, Ly6C
int
, F4/80-, 
Ly6G+ (Figure 3.5D). Moreover TAM were recognized as CD11b+, Ly6C-, F4/80+ (R3, Figure 
3.5E), while two populations of monocytes were classified as CD11b+, Ly6C
high
, F4/80- (R1) 
and CD11b+, Ly6C
high
, F4/80+ (R2). On the basis of this gating strategy D6-KS tumors were 
found to have increased TAM but a reduced number of monocytes. Moreover we checked 
for the polarization skewing of tumor associated macrophages, analyzing the expression of 
the M1 marker MHC-II and the M2 marker mannose receptor, also known as CD206. 
Compared to D6+KS, TAM infiltrating D6-KS tumors had decreased levels of MHC-II and a 
tendency to have more CD206 (Figures 3.5F and 3.5G, respectively).  
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Figure 3.5 - Increased leukocyte infiltrate in D6-negative tumors. (A) Representative dot plot 
analysis of an enzymatically digested tumor stained and analyzed by flow cytometry showing gating 
strategy to detect tumor cells (KS) and infiltrating leukocytes (IL) analyzing live cells and singlets in 
single cell suspension for the expression of GFP and CD45. Mean ± SEM of the total number of GFP+ 
KS cells (B), and CD45+ infiltrating leukocytes (C) at day 7 and 14 after inoculation of D6+KS (■) and 
D6-KS (□) are shown. (D) Representative dot plot and mean of the percentage of CD11b+ Ly6G+ 
neutrophils in the CD45+ gate and (E) immature monocytes (R1: Ly6Chigh, F4/80-), monocytes (R2: 
Ly6Chigh, F4/80+) and macrophages (R3: Ly6C-, F4/80+) in the CD11b+ Ly6G- gate at day 7. 
Representative histogram plot and mean fluorescence intensity (MFI) of MHC-II (F) and CD206 (G) 
expression of R3 gated cells in D6+ (black line) and D6-KS (grey area) tumors. All gates are based on 
isotype controls. In all figures histograms represent the mean ± SEM of at least three independent 
experiments (n = 5 tumors/group) of D6+KS (black bar) or D6-KS (white bar). *p<0.05, **p<0.005. 
 
4. Results 
   70 
Similar results were also obtained differentiating in vitro bone marrow derived 
macrophages (BMDM) with tumor conditioned medium (TCM) derived from D6+ or D6- KS 
cells. In fact BMDM after 7 days of culture with D6-TCM showed higher percentage of 
macrophages as compared to BMDM cultured with D6+KS TCM (Figure 3.6A). Moreover 
increased levels of the M2 marker CD206 (Figure 3.6 B) and reduced levels of the M1 marker 
MHC-II (Figure 3.6 C) were induced by TCM from D6-KS as compared to D6+KS cells. All 
together in vitro and in vivo data indicate that reduced levels of D6 are associated with 
increased TAM recruitment at tumor site and their local maturation towards M2-like 
polarization. 
 
Figure 3.6 - Increased M2-like macrophage differentiation induced by D6-KS supernatant. (A) 
Representative dot plot analysis and percentage of immature monocytes (R1), monocytes (R2) and 
macrophages (R3) of WT BMDM cultured with D6-KS (white bar) or D6+KS (black bar) TCM labeled 
and gated as described in Figure 3H. Relative MFI of MHC-II (B) and CD206 (C) on R3 gated 
macrophages cultured with D6-KS (white bar) or D6+KS (black bar) TCM. Mean ± SEM of at least 
three independent experiments is shown. *p<0.05, **p<0.005. 
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4.1.6. CCR2-dependent TAM recruitment is required for KS growth 
Analyzing tumor infiltrated leukocytes we found that D6 expression has a significant 
impact on the number of neutrophils, monocytes and tumor associated macrophages but it 
also has qualitative effects on infiltrating macrophages, skewing them toward a more M1 
phenotype. To directly assess the role of different populations of tumor-infiltrating 
leukocytes on KS growth, depletion experiments were performed. 
 
4.1.6.1. Neutrophils depletion did not affect D6-KS growth 
Firstly neutrophils, which have been observed to be significantly increased in tumors 
lacking D6, were depleted. The depletion was achieved by injecting mice 1 day prior to KS-
IMM inoculation and every 3 days thereafter with anti-Ly6G 1A8 MoAb whereas control 
animals received purified whole rat IgG2a. Anti-Ly6G administration completely depleted 
neutrophils present in the blood (Figure 3.7 A) and in the KS tumors (Figure 3.7 B) but no 
reductions or modifications in the progression of D6- and D6+KS tumors were seen (Figure 
3.7 C). This data indicate that neutrophils are not involved in supporting D6-KS tumor 
growth. 
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Figure 3.7 – Neutrophil depletion did not affect KS tumor growth. Mice inoculated with D6-KS or 
D6+KS cells were treated with a blocking antibody against Ly6G (1A8). Representative dot plot 
analysis at day 25 of circulating (A) and tumor-associated (B) PMN (CD11b+, Ly6G+) of D6-KS bearing 
mice before and after 1A8 treatment. The graph reports the percentage ± SEM of PMN in D6-KS 
tumors. (C) D6- (solid line) and D6+KS (dashed line) tumor volume after s.c. inoculation in PBS or 1A8-
treated mice. Results are expressed as mean ± SEM. ***p<0.0005, D6+ versus D6-KS. 
 
 
 
 
4. Results 
   73 
4.1.6.2. Inhibition of CCR2-dependent macrophage recruitment restrains D6-
KS growth 
Once neutrophils were excluded as population mainly involved in supporting tumor 
growth, monocyte and macrophage recruitment at tumor site was inhibited by antagonizing 
CCR2, chemokine receptor fundamental for directional monocyte traffic. Mice were treated 
with the antagonist of CCR2 called RS-504393 by oral gavage from the day of KS-IMM 
injection until the day animals were sacrificed. The treatment and the associated reduction 
of circulating monocytes (Figure 3.8 A) and infiltrating TAM (Figure 3.8 B) had no effect on 
D6+KS growth, but significantly inhibited D6-KS growth rate at early time points (Figure 3.8 
C). The fact that a CCR2 antagonist only partially inhibited the growth of D6-KS is consistent 
with the fact that these lesions contain increased levels of other monocyte attracting 
chemokines (Figure 3.4 B and 3.4 C).  
Finally in order to evaluate the importance of CCR2-expressing macrophages in 
endorsing tumor, WT or CCR2
-/-
 BMDM were co-injected with D6+KS in nude mice. When co-
injecting with WT but not CCR2
-/-
 BMDM D6+KS growth improved and became similar to D6-
KS one (Figure 3.8D). In conclusion data indicate the relevance of CCR2 expression by TAM 
for their pro-tumoral activity beyond their local recruitment 
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Figure 3.8 – KS growth is sustained by TAM recruitment. Mice inoculated with D6-KS or D6+KS cells 
were treated with the specific CCR2 antagonist RS-509343 (RS). (A) Representative flow cytometry 
gating scheme at day 25 of circulating monocytes (CD11b+, CD115+). (B) CD11b+Ly6G- tumor 
infiltrate in PBS-treated versus RS-treated D6-KS tumors. The monocyte-macrophage population was 
gated as described in figure 5E and number ± SEM is reported in the graph. (C) D6-KS (solid line) and 
D6+KS (dashed line) tumor volumes after treatment with PBS or RS. Panel D shows tumor growth of 
D6+KS, injected alone (■) or with WT (dotted line) or CCR2
-/-
 BMDM (□). In all panels data are 
representative of two independent experiments (n = 8 mice/group). Results are expressed as mean ± 
SEM. *p<0.05, ***p<0.0005, D6+ versus D6-KS; #p<0.05 treatment versus control. 
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4.1.7. Increased production of VEGF-A and angiogenesis in D6-KS 
From in vivo experiments we established the importance of CCR2 expressed by 
macrophages at tumor site, underlining a relevant effect of the receptor beyond cell 
recruitment. In order to identify the mechanism by which CCR2+ TAM promote KS growth, 
the content of the angiogenic factor VEGF-A  and the expression of the endothelial cell 
marker CD31 were investigated. In fact by the literature there are evidences indicating that 
CCR2 engagement can induce VEGF-A production through an autocrine pathway requiring 
COX2 activity [285], [286]. While no difference was found for human VEGF-A content (data 
not shown), D6-incompetent tumors showed higher levels of murine VEGF-A as compared to 
D6-competent tumors (Figure 3.9 B). Moreover immunohistochemistry analysis with anti-
CD31 performed on sections of KS tumors showed that in D6 expressing tumors few vascular 
structures were present, whereas D6-KS tumors were highly vascularized (Figure 3.9 A). No 
differences were seen between D6- and D6+KS tumors in terms of necrosis, as assessed by 
hematoxylin-eosin staining of histological sections (data not shown). Finally to define D6-KS 
derived factor influencing VEGF-A production in vitro experiments were performed. BMDM 
were cultured with MCSF and 25% of D6+ or D6-KS TCM and levels of VEGF-A were 
measured. The conditioned medium of D6-KS but not D6+KS cells increased the production 
of mVEGF-A by BMDM (Figures 3.9 C). Interestingly, VEGF-A production induced by D6-KS 
TCM was reverted when CCR2
-/-
 BMDM were used (Figures 3.9 C), indicating a key role of 
tumor-derived CCR2 agonists in the acquisition of a pro-angiogenic phenotype. Furthermore 
to check the mechanism involved in CCR2-induced VEGF production, the COX2 inhibitor 
indomethacin was used to treat BMDM during their culture. The treatment with 
indomethacin inhibited VEGF-A production by BMDM stimulated with D6-KS TCM (Figures 
3.9 C). In conclusion CCR2 agonists, which are efficiently degraded in D6+KS tumors, induce a 
pro-angiogenic phenotype of TAM that sustain D6-KS growth.  
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Figure 3.9 – CCR2
+
 TAM sustain angiogenesis in D6-KS tumors. Panel A shows mean ± SEM of the 
number of CD31+ cells (semiquantitative score: 0: no positive cells; 1: 0÷20% positive cells; 2: 
20÷40% positive cells; 3: 40÷60% positive cells; 4: 60÷80% positive cells; 5: > 80% positive cells). 
Score was given as the mean from five random fields for each sample. Representative images of 
mCD31 immunohistochemical analysis in D6+KS and D6- KS tumors at day 7 after implantation are 
shown (magnification 20x). Panel B shows mVEGF-A concentration in homogenized D6+KS (■) and 
D6-KS (□) tumors at indicated time points. Data are expressed as the mean ± SEM (n = 4/each group) 
normalized for the tumor volume. Panel C shows mVEGF-A production by WT and CCR2
-/-
 BMDM 
stimulated for 6 days with D6+KS (■) or D6-KS (□) TCM or with normal medium (■) and where 
indicated with indomethacin. Mean ± SEM of at least three independent experiments is shown. 
Results are expressed as mean ± SEM. *p<0.05, **p<0.005, ***p<0.001. 
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4.1.8. Role of the ERK pathway in the downregulation of D6 expression 
From in vivo experiments D6 resulted to act as oncosupressor molecule, inhibiting KS 
growth by shaping tumor microenvironment. At the same time, analysis of KS sections from 
patients demonstrated an inverse correlation between D6 expression and tumor 
aggressiveness, supporting in vivo results. Therefore, to understand the mechanism by which 
tumor cells are able to down-regulate D6 expression, in vitro experiments using KS-IMM cell 
line were performed. Firstly K-Ras/B-Raf/MEK pathway was investigated, being it involved in 
HHV8 reactivation process in KS [287]. Furthermore K-Ras activating mutations or 
amplifications are frequently found in KS lesions, particularly in advanced stages [288], [289]. 
Indeed KS-IMM cell line was analyzed to examine the presence of mutations on this 
pathway. While no mutations in the K-Ras gene were detected, the B-Raf V600E oncogenic 
mutation was present (Figure 3.10 A). Consistent with the known ability of activated B-Raf to 
phosphorylate MEK, that respectively activates ERK1/2 [290], KS-IMM, in basal conditions, 
showed high levels of ERK1/2 phosphorylation (Figure 3.10 B), which were inhibited by B-Raf 
inhibitor PLX4032 and MEK inhibitor U0126. The suppression of the constitutive activation of 
the ERK pathway by these inhibitors resulted in a concomitant up-regulation of D6 
expression in KS-IMM, indicating that, in KS-IMM, D6 expression is down-regulated as a 
consequence of the constitutive activation of B-Raf/MEK/ERK pathway (Figure 3.10 C). 
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Figure 3.10 – Downregulation of D6 expression by ERK activation. (A) Sequence chromatogram of 
BRAF exon 15 of DNA from KS-IMM cells. The thymine (T) to adenine (A) transition introduces a 
substitution of amino acid valine to glutamic acid at codon 600 (V600E). (B) Western blot analysis of 
ERK1/2 phosphorylation and (C) qRT-PCR of D6 expression in KS-IMM cells treated with UO126, 
PLX4023 or their combination. *p<0.05, **p<0.005. 
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4.1.9. ERK activation, macrophage infiltration and D6 expression in human KS 
Once identify the mechanism involved in the down-regulation of D6 in KS-IMM, we 
wanted to assess its actual clinical relevance in patients. For that reason sections from KS 
patients at stage IB were stained by immunohistochemistry for ERK phosphorylation and, in 
agreement with in vitro data, an inverse correlation between ERK1/2 activation (anti-pERK 
staining) and D6 expression (n=10) (Figure 3.11 A) was observed. Moreover we wanted to 
validate the hypothesis obtained with the in vivo model concerning the ability of D6 to shape 
KS microenvironment toward an anti-tumoral phenotype. Indeed immunohistochemical 
analysis for identification of TAM and their polarization were performed, respectively with 
anti-CD68 and anti-CD163 staining. The results showed increased infiltration of CD68+ and 
CD163+ (Figure 3.11B) macrophages in KS lesions characterized by a rapid progression rate 
(stage IB) as compared with slow progressing ones (stage IA) and they also highlight a 
significant inverse correlation between D6 expression levels and the number of CD68+ 
(p=0.039, n=18) and CD163+ cells (p=0.003 n= 18) (Figure 3.11C). Taken together, these 
results are consistent with data obtained in the KS-IMM-based experimental model, 
supporting the notion that in KS progression activation of the B-Raf/MEK/ERK pathway 
mediates down-regulation of D6, resulting in increased CCR2-dependent TAM infiltration 
and their local activation towards a tumor-promoting M2-like phenotype. 
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Figure 3.11 – inverse correlation between D6 expression and ERK activation, macrophage 
infiltration and M2 macrophage phenotype. (A) D6 and pERK1/2 immunohistochemical analysis in 
cutaneous maculo-nodular KS lesions from stage IB 28 patients. Scatter plot reports mean values ± 
SEM from five random fields evaluated for number of pERK1/2 positive cells using a semiquantitative 
scale (1: 0÷25% positive cells; 2: 25÷50% positive cells; 3: 50÷75% positive cells; 4: 75÷100% positive 
cells) in D6
low
 (score 1-2) and D6
high
 (score 3- 4) lesions. In the right panel representative 
immunohistochemical analysis of KS lesions from two patients stained for human D6 (score 1 on the 
left and 3 on the right) and pERK1/2 (score 3 on the left and 1 on the right). Magnification 20x. (B) 
Mean and SEM of CD68 and CD163 positive cells and (right panel) representative 
immunohistochemical staining (magnification 10X; positive cells are pink) in maculo-nodular lesions 
from HIV-negative patients with slow (stage IA) and rapid (stage IB) progression rate. Five random 
fields for each sample were counted. (C) Linear regression analysis of D6 expression levels and CD68 
(left panel) and CD163 (right panel) number of positive cells/fields in cutaneous maculo-nodular KS 
lesions from stage IA (○) and IB patients (●). *p<0.05, **p<0.005. 
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4.2. CCR2 expression by macrophages promotes tumor progression 
through induction of IL-10 and VEGF production 
Chemokines and chemokine receptors have been intensively studied in tumor 
biology, in fact they are key players in several stages of tumor progression, in particular in 
leukocyte recruitment at tumor site, but also in promoting angiogenesis and metastatization 
[192]. One of the best characterized chemokine in supporting tumor development is CCL2, 
indeed, this chemokine, together with its receptor CCR2, displays different roles in tumor 
biology. Firstly CCR2 has been demonstrated to be crucial in monocyte mobilization from 
bone marrow into the circulation [110, 291, 292] and in monocytes-macrophage recruitment 
at tumor site [126, 293] but in the literature there are also data highlighting its potential role 
in macrophage polarization [201]. 
 
4.2.1. Lack of CCR2 skew macrophages toward M1 phenotype 
In order to better understand the possible implication of CCR2 in macrophage 
polarization wt and CCR2
-/-
 bone marrow derived macrophages (BMDM), cultured for 7 days 
with M-CSF, were polarized toward M1 or M2 phenotype, by using LPS+IFNγ or IL-4, 
respectively. After 24 hours of stimulation, wt and CCR2
-/-
 BMDM were analyzed for M1 and 
M2 marker expression by flow cytometry and quantitative PCR. No differences were found 
by FACS analysis, nor in expression of the M1 marker MHCII do neither in the M2 marker 
Relmα (Figure 3.2.1 A, B). Furthermore, quantitative PCR of M2 genes, such as Relmα and 
Arginase-1 (Figure 3.2.1 E, F), did not show differences between wt and CCR2
-/-
 M2-polarized 
BMDM. Nevertheless, when M1-polarized BMDM were analyzed for iNOS and IL-12p40 
(Figure 3.2.1 C,D) expression, CCR2
-/-
 macrophages showed an enhanced expression of these 
typical M1 genes. Moreover, macrophages lacking the chemokine receptor also displayed a 
decreased production of the anti-inflammatory cytokine IL-10 (Figure 3.2.1 G). 
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Figure 3.2.1 – Increased expression of inflammatory gene in CCR2
-/-
 M1-polarized BMDM. M1 and 
M2-polarized wt (white bar) and CCR2
-/- 
(black bar) BMDMs were analyzed by flow cytometry, for 
expression of MHCII (A) and Relmα (B), or by qPCR for measuring expression of iNOS (C), IL-12p40 
(D), Relmα (E) and Arg-1 (F). Production of IL-10 was measured by ELISA in M1-supernatants. Data 
are expressed as the mean concentration ± SEM of at least three independent experiments. 
**p<0.005 
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4.2.2. The improvement of inflammatory gene expression in CCR2-/- BMDM 
correlates with an impairment of IL-10 and VEGF production  
M1 polarization is modelled in vitro by interferon-γ (IFNγ) and lipopolysaccharide 
(LPS) stimulation, dictating a transcriptional response that shapes the phenotype and 
function of macrophages. In order to dissect the signaling pathway interacting with the one 
of CCR2, wt and CCR2
-/-
 BMDMs were stimulated for 24h with LPS alone. Once again CCR2
-/- 
macrophages showed an increased expression of inflammatory genes, such as iNOS and IL-
12p40 (Figure 3.2.2 A, B), suggesting that CCR2 signaling could interact with TLR4 pathway. 
Moreover, we also found that macrophages lacking CCR2 produced lower levels of the M2-
related cytokines IL-10 and VEGF (Figure 3.2.2 C, D).  
 
Figure 3.2.2 - Increased inflammatory gene expression in CCR2
-/-
 LPS-stimulated BMDM. Wt (white 
bar) and CCR2
-/- 
(black bar) BMDMs were analyzed after 24h of LPS stimulation by qPCR for 
expression of iNOS (A) and IL-12p40 (B). Production of IL-10 and VEGF was measured by ELISA in 
BMDM supernatants after 4, 8 and 24h of LPS stimulation. Data are expressed as the mean 
concentration ± SEM of at least two independent experiments. **p<0.005 
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4.2.3. CCR2 inhibition on monocytes affects IL-10 production  
Because previous experiments highlighted a possible crosstalk between TLR4 and 
CCR2 pathways, we wanted to confirm also in the human setting that inhibition of CCR2 
signaling would turn into a decreased production of IL-10. Indeed, human monocytes were 
treated with the CCR2 antagonist RS-504393 that inhibited ERK1/2 phosphorylation after 
CCL2 stimulation (Figure 3.2.3 A) and it has been demonstrated to be not toxic with Annexin 
V/7AAD staining (data not shown). LPS stimulated monocytes treated with RS displayed 
reduced IL-10 mRNA and protein (Figure 3.2.3 B, C, D). RS has a dose-response effect and at 
5µM inhibits nearly 30% of IL-10 present in supernatants. 
 
Figure 3.2.3 – Decreased IL-10 production in RS-treated human monocytes. ERK1/2 phosphorylation 
after CCL2 stimulation (A) and viability analysis by annexin V/7AAD (B) of RS-treated human 
monocytes. (C) IL-10 mRNA production was measured by qPCR after 16 hours of LPS stimulation. 
Detection of IL-10 protein by ELISA assays in supernatants was performed after 6 (D) and 24h (E) of 
LPS stimulation. Data are expressed as the mean concentration ± SEM of at least two independent 
experiments. *p<0.05 
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4.2.4. CCR2 signaling interacts with NF-κB and p38 pathways  
The inhibition of IL-10 and the increase expression of inflammatory genes suits with a 
defect in TLR4 pathway activation. In fact, TLR4 engagement entails the phosphorylation of 
NF-kB and p38/MAPK. It consequently leads to expression of inflammatory genes and then 
to the production of IL-10, which in turn, switch off the inflammation. 
The activation of NF-kB and p38/MAPK pathways was analyzed by western blot in wt 
and CCR2
-/-
 BMDMs after 10, 30 and 240 minutes after LPS stimulation. NF-kB p65-subunit is 
early phosphorylated, with the maximum level of activation at 10 minutes (Figure 3.2.4 A, B), 
whereas p38/MAPK (Figure 3.2.4 A, C) started to be phosphorylated 30 minutes after LPS 
stimulation. Both pathways have been detected to be restrained in CCR2
-/- 
macrophages 
(Figure 3.2.4 B, C). 
 
Figure 3.2.4 – Restraint NF-kB and p38 activation in CCR2
-/-
 macrophages. NF-Kb (A, B) and p38 (A, 
C) phosphorylation after LPS stimulation was analyzed by western blot and bands were quantified by 
densitometry. Data are expressed as the mean concentration ± SEM of at least two independent 
experiments.  
4. Results 
   86 
4.2.5. CCR2 expressed by TAM improves tumor growth 
Our data indicate that macrophages lacking CCR2 hold a more inflammatory 
phenotype and express lower levels of M2-like cytokines, such as the anti-inflammatory 
cytokine IL-10 and the pro-angiogenic VEGF. Because of these evidences we decided to 
investigate the biological role of CCR2 expressed by TAM in tumor biology. The Lewis lung 
carcinoma cell line, LLC or 3LL, was co-injected together with wt or CCR2
-/-
 macrophages, 
with a ratio of 1:1, in the flank of C57BL/6 mice. The results showed that co-injection of 3LL 
with CCR2
-/-
 macrophages provoke an impairment of tumor growth (Figure 3.2.5 A), an 
increase of mice survival (Figure 3.2.5 B) associated to a decreased production of VEGF-A 
(Figure 3.2.5 C). Furthermore tumor infiltrated leukocytes were analyzed. No differences 
were in monocytes and macrophages percentages (Figure 3.2.5 E), whereas there is a 
tendency to have more neutrophils (Figure 3.2.5 D) in tumors containing CCR2
-/-
 
macrophages than wt counterpart. Nevertheless, analyzing TAM phenotype we observed 
that the one derived from tumors co-injected with CCR2
-/-
 BMDMs showed a more M1 
phenotype, expressing higher levels of MHCII and lower levels of CD206 (Figure 3.2.5 F-G). 
Looking then at lymphocytes, tumors holding CCR2
-/-
 macrophages resulted to have an higher 
number of T cells (Figure 3.2.5 H) and analyzing their phenotype, both CD4+ T-helper and 
CD8+ T-cytotoxic cells were increased (Figure 3.2.5 I-L), correlating with the impaired tumor 
growth. Expansion of T lymphocytes can be modulated by the activity of FOXP3+ regulatory T 
cells, which are primary located in lymphoid organs, such as lymph nodes and spleen, acting 
by suppressing tumor-specific immune response. FOXP3+ regulatory T cells in spleens of mice 
holding tumors co-injected with CCR2
-/-
 macrophages were detected to be decreased (Figure 
3.2.5 M). 
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Figure 3.5 – Impaired tumor growth and increased mice survival of tumors co-injected with CCR2
-/-
 
macrophages. Panels A and B report the growth rate and percentage of survival of tumors co-
injected with wt (black line) or CCR2
-/-
 (dashed line) macrophages. After 14 days from tumor 
injection, tumors were explanted and analyzed for VEGF-A (C) production and for tumor infiltrating 
leukocytes: neutrophils (D), monocyte-macrophage cells (E), total number of T lymphocytes (H), 
CD4+ (I) and CD8+ (L) T lymphocytes. Mean fluorescence intensity (MFI) of MHC-II (F) and CD206 (G) 
expression of TAM. (M) Percentage of FOXP3+ Treg cells in spleens of mice injected with tumor cells 
and wt or CCR2
-/- 
macrophages . (n = 5 tumors/group). *p<0.05. 
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5. Discussion 
 
Chemokines are important components of cancer-related inflammation affecting 
tumor progression in multiple pathways, including tumor cell proliferation and survival, 
invasion and metastasis, leukocyte recruitment, and angiogenesis [294-296]. By targeting to 
degradation most inflammatory CC chemokines and limiting their bioavailability in tissues, 
the atypical chemokine receptor D6 represents an emerging mechanism of regulation of the 
chemokine system [166]. D6 has a well-established non-redundant role in the control of the 
inflammatory response, regulating the traffic and the activity of cells of the mononuclear 
system, in particular inflammatory monocytes [177], and also has a negative role in 
inflammation-driven tumor development in experimental models [175, 188]. In the human 
setting, D6 has been reported to be expressed by choriocarcinoma cell lines [172], in breast 
[190] and vascular tumors [170, 179], but its actual relevance in human cancer has not yet 
been established. 
KS is a malignancy caused by the interplay of LEC infection with HHV8, oncogenic 
events, and a tumor-promoting chronic inflammatory milieu [273]. Considering the major 
role of inflammatory chemokines in KS pathogenesis and the fact that LEC express the 
atypical chemokine receptor D6 [243], analysis of its expression was performed on biopsies 
of KS lesions. D6 was found expressed by HHV8-infected spindle-shape KS cells, and its 
expression was inversely correlated with tumor aggressiveness, both when comparing 
maculonodular KS lesions retrospectively classified according to their progression rate 
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(group A versus group B stage I lesions) and when comparing maculo-nodular lesions of HIV-
seronegative and -seropositive patients, which typically show a slow and rapid progression 
rate, respectively. 
To put into a test the hypothesis emerging from these observations that reduction of 
D6 expression might be part of the natural KS progression process, we set up an 
experimental model based on the tumor cell line KS-IMM, which has been derived from a 
human KS lesion and induces KS-like sarcomas retaining most features of the parental tumor 
when injected subcutaneously in nude mice [283]. When compared to D6-expressing KS, D6-
incompetent KS display increased tumor growth in vivo but not in vitro, suggesting that D6 
expression may influence KS growth by interfering with the tumor microenvironment. 
Consistent with this, D6-negative tumors were found to be characterized by increased levels 
of inflammatory chemokines and profound changes in the intratumoral leukocytic infiltrate 
composition. D6-negative tumors showed an increased infiltration of TAM and tumor 
associate neutrophils. Despite tumor associate neutrophils have been reported to be 
important for tumor growth by activating angiogenic factors [210], the selective depletion of 
Ly6G+ cells did not affect KS growth. Conversely, inhibition of monocyte recruitment and 
TAM infiltration by the use of a CCR2 antagonist inhibited the growth rate of D6-KS tumors. 
Direct assessment of the requirement of TAM for KS growth was demonstrated by adoptive 
transfer experiments showing that coinjection of BMDM promoted D6+KS growth. D6 
expression downregulation (in patients KS lesions) or absence (in the KS-IMM model) was 
also correlated with an increased M2-like polarization of TAM. Furthermore, the same M2-
skewed phenotype was found in BMDM cultured with TCM taken from D6-negative tumors. 
These results collectively indicate that downregulation of this chemokine scavenger receptor 
at the tumor site not only allowed inflammatory CC chemokines to recruit more monocytes, 
but also directly promoted their pro-tumoral M2-like polarization [201]. 
Several studies have indicated that TAM have a pivotal role in the regulation of tumor 
angiogenesis, especially at early stages of tumor progression [297]. Here we report that D6-
incompetent tumors, in addition to having more TAM, had increased amounts of VEGF-A and 
intratumoral angiogenesis. Using KS-conditioned media it was found that increased VEGF-A 
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production by BMDM required CCR2 expression and an autocrine loop triggered by CCR2 
agonists involving induction of COX2 and PGE2 production [285, 286]. Furthermore, 
requirement of CCR2 expression on macrophages for KS growth was directly demonstrated 
by adoptive transfer experiments, in which wt but not CCR2
-/-
 BMDM were able to sustain KS 
tumor growth. Several studies have correlated CCR2+ TAM infiltration with increased tumor 
angiogenesis and VEGF-A production [293], but the direct role of this chemokine receptor in 
the production of VEGF-A has not been assessed. By providing direct evidence that besides 
its well-known chemotactic function CCL2 can also directly affect the angiogenic potential of 
TAM, these results may be relevant to tumors other than KS characterized by elevated CCL2 
levels, including breast and prostate tumors [187]. 
In an effort to elucidate the molecular basis responsible for D6 downregulation 
associated with tumor progression, we focused on the K-Ras/B-Raf/MEK/ERK1/2 pathway, as 
oncogenic mutations or amplifications interfering with the activity of this pathway are 
frequently observed in late-nodular KS lesions and angiosarcomas [288, 298], where its 
activity has been shown to support enhanced expression of growth factors and cytokines, 
including VEGF-A [299]. Consistently with their aggressiveness in vivo, KS-IMM cell line, 
originally established from an advanced KS lesion, harbors an activating oncogenic mutation 
in the B-Raf gene and shows high levels of constitutive ERK1/2 activity. In this cell system, D6 
expression was found to be under control of this signaling pathway, as its inhibition either by 
B-Raf or ERK inhibitors resulted in upregulation of D6. This functional link was then 
confirmed in KS lesions, where D6 expression levels were found to be inversely correlated 
with tumor aggressiveness, ERK1/2 activation, and number of infiltrating TAM, whose 
number and M2-like phenotype was on the other hand directly correlated with tumor 
aggressiveness. The results presented here suggest that during KS progression oncogenic 
events activate the ERK1/2 pathway which induces D6 downregulation in tumor cells. This 
allows tumor-derived inflammatory chemokines, and in particular CCR2 ligands, to recruit 
monocytes and sustain their local polarization toward M2-like TAM, which support a VEGF-
A-dependent angiogenetic switch promoting tumor growth. Targeting these components of 
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the KS tumor microenvironment may thus represent alternative or complementary 
therapeutic strategies. 
From KS study CCL2 resulted to be an important player in tumor promotion, 
considering that it affects angiogenic potential of TAM, by inducing VEGF production and it 
also seems to directly promote their pro-tumoral M2-like polarization. Moreover, in the 
literature there are increasing evidences implicating CCL2 in cancer progression and 
metastatization. Indeed, CCL2 has been demonstrated to be expressed in several tumors, 
such as sarcomas, gliomas, and cervical, ovarian, bladder, breast, and lung tumors [68, 300] 
and more recently it has been described in prostate cancer bone metastasis [301]. In certain 
carcinomas, CCL2 also strongly correlated to TAM infiltration and it has been suggested to be 
involved in Th2 polarization [302], whereas in vitro data demonstrated CCL2 to support M2-
like phagocytic functions promoting tumor growth in human monocytic cells, by induction of 
CD206 expression and macrophage autophagy [201]. Taken together all these evidences 
indicate that chemokines and in particular CCL2 can be fundamental in supporting tumor 
promotion through TAM polarization, but the mechanism whereby it happens is still 
unknown. Therefore, we decided to investigate the polarization process in macrophages 
deficient for CCL2 receptor, CCR2. Whereas, unexpectedly, no differences were found in M2 
polarization, an over-expression of inflammatory genes was shown in CCR2
-/-
 macrophages 
both polarized toward M1 phenotype or stimulated with LPS alone. The increased 
inflammation is associated with a defect in the production of the anti-inflammatory cytokine 
IL-10, which plays a fundamental role in turning off inflammatory gene expression in order to 
avoid an excessive inflammatory response [303-305]. The decreased IL-10 production was 
confirmed in human monocytes, by treating them with the CCR2 antagonist RS-504393, 
supporting the evidence that, during LPS stimulation, CCR2 signaling interacts with TLR4 
pathway straightening the production of IL-10. The complex response to LPS is mediated by 
different proteins and comprehends the activation of NF-kB and p38/MAPK [306, 307]. We 
investigated the phosphorylation state of this two proteins and we found that CCR2
-/-
 
macrophages, after LPS stimulation, showed a decreased activation of both p65 NF-kB-
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subunit and p38/MAPK than wt, confirming that CCR2 signaling acts in synergism with TLR4 
pathway for controlling the inflammatory response through the production of IL-10.  
Consequently, in order to assess the in vivo role of CCR2 expressed by TAM in 
skewing their polarization toward an M2 phenotype. When CCR2
-/-
 macrophages were co-
injected in mice with tumor cells (3LL), an impaired tumor growth and an increased mice 
survival were obtained. These tumors were also found to produce less VEGF-A than tumors 
co-injected with wt macrophages, confirming the autocrine loop sustained by CCR2 in 
macrophage production of the pro-angiogenic cytokine VEGF-A [285, 286, 293]. Looking then 
to TAM, a skewing toward a more M1 phenotype was showed by TAM of CCR2
-/-
 
macrophage-holding tumors, than wt counterpart, highlighting the importance of CCR2 in 
modeling tumor microenvironment and shaping macrophage functions. Furthermore, 
tumors co-injected with CCR2
-/-
 BMDMs also showed an increased number of tumor 
infiltrating T lymphocytes, both CD4+ and CD8+ T cells, which play an important contribution 
in tumor suppression. The number of T cells and their proliferation ability can be repressed 
by T regulatory cells which produce high levels of anti-inflammatory cytokines and in 
particular of IL-10 and TGFβ. IL-10 is also known to play a direct role in T-reg genesis [309]. 
Indeed, in our tumor model, the number of T-reg cells was found to be decreased in the 
spleen of animals bearing tumor co-injected with CCR2
-/-
 macrophages, which produce lower 
amount of IL-10, in comparison with wt counterpart. In conclusion, the concurrence of CCR2 
and TLR4 signaling and their synergic control of the inflammatory response, resulted in 
macrophage skewing toward M2 resolving-phenotype but also in shaping tumor 
microenvironment, inducing angiogenesis and T-reg proliferation, finally promoting tumor 
growth. 
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